STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 10

TO: Rita Mitra **Location: CM1/9B03/9B01** **Art Unit: 1653** **Monday, September 29, 2003** **Case Serial Number: 09/887855**	**From: Alex Waclawiw** **Location: Biotech-Chem Library** **CM1-6A02** **Phone: 308-4491** **Alexandra.waclawiw@uspto.gov**

Search Notes

Access DB# 104467

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name RITA MITRA Examiner # : 77995 Date: 9/23/03
Art Unit 1653 Phone Number 30 605-1211 Serial Number 09/887855
Mail Box and Bldg/Room Location 9801 CM1/ Rm 9803 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. ME

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention "Lectin SS3939 DNA and Polypeptides"

Inventors (please provide full names): ANDERSON, DIRK M.

Earliest Priority Filing Date: December 23, 1998

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

I would request an expedited literature search (Patent and Non-patent both) on above application because this is a date case. No Seq Search

The search should cover a polypeptide termed "SS3939", that ~~can be used as~~ has use for peptide fragmentation study, molecular weight measurement and for use in protein sequencing using tandem mass spectrometry.

Keywords:
Lectin, sugar-binding protein, Lectin domain

Elected claims: claims 3, 4, 5 & 12

C. Chan
Rich

STAFF USE ONLY

Point of Contact:
Alexandra Waclawiw
Technical Info. Specialist
CM1 6A02 Tel: 308-4491

Searcher:
Searcher Phone #:
Searcher Location:
Date Searcher Picked Up: 9-29-03
Date Completed: 9-29-03
Searcher Prep & Review Time:
Clerical Prep Time: 8
Online Time: 21

Type of Search
NA Sequence (#)
AA Sequence (#)
Structure (#)
Bibliographic ✓
Litigation
Fulltext
Patent Family
Other

Vendors and cost where applicable
STN $135.00
Dialog
Questel/Orbit
Dr Links
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

```
=> fil hcaplus wpids biosis medline embase
FILE 'HCAPLUS' ENTERED AT 07:45:10 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 07:45:10 ON 29 SEP 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 07:45:10 ON 29 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 07:45:10 ON 29 SEP 2003

FILE 'EMBASE' ENTERED AT 07:45:10 ON 29 SEP 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

=> d his l1-l12

     (FILE 'HCAPLUS, WPIDS, BIOSIS, MEDLINE, EMBASE' ENTERED AT 07:36:20 ON 29
     SEP 2003)
L1             4 S SS3939 OR SS 3939
L2             1 S (SS3939 OR SS 3939)/AB
L3             4 S L1 OR L2
L4             3 DUP REM L3 (1 DUPLICATE REMOVED)
L5         25589 S CHROMOSOME (3A) 11
L6            33 S L5 AND LECTIN#
L7       2744383 S (DNA OR NUCLEIC ACID# OR CDNA)
L8            22 S L6 AND L7
L9        579390 S PROTEIN (2W) SEQUEN? OR POLYPEPTIDE#
L10           13 S L8 AND L9
L11           12 DUP REM L10 (1 DUPLICATE REMOVED)
L12           11 S L11 NOT L4

=> d bib abi it l4 1-3;d bib ab it l12 1-11
'ABI' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'
ENTER DISPLAY FORMAT (BIB):end
=> d bib ab it l4 1-3;d bib ab it l12 1-11

L4   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2003 ACS on STN
AN   2001:868629  HCAPLUS
DN   136:15957
TI   Human nucleic acids and their encoded proteins and antibodies
IN   Birse, Charles E.; Rosen, Craig A.
PA   Human Genome Sciences, Inc., USA
SO   PCT Int. Appl., 2081 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 91
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2001090304      A2    20011129      WO 2001-US16450  20010518
     WO 2001090304      A3    20020510
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
```

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001041411 A5 20010820 AU 2001-41411 20010208
AU 2001074888 A5 20011203 AU 2001-74888 20010518
PRAI US 2000-205515P P 20000519
US 2000-241221P P 20001020
US 2000-241786P P 20001020
WO 2001-US16450 W 20010518

AB The present invention relates to 1405 novel human polynucleotides and the polypeptides encoded by these polynucleotides and the use of the polypeptides for detecting disorders. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compns. for inhibiting the prodn. and function of the polypeptides of the present invention.

IT Genetic mapping
(chromosomal; human nucleic acids and their encoded proteins and antibodies)

IT Animal tissue
(expression patterns in; human nucleic acids and their encoded proteins and antibodies)

IT Genetic methods
(gene discovery; human nucleic acids and their encoded proteins and antibodies)

IT Disease, animal
Drug screening
Drugs
Epitopes
Gene therapy
Molecular cloning
Protein sequences
Susceptibility (genetic)
cDNA sequences
(human nucleic acids and their encoded proteins and antibodies)

IT Proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(human nucleic acids and their encoded proteins and antibodies)

IT Antibodies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human nucleic acids and their encoded proteins and antibodies)

IT Diagnosis
(mol.; human nucleic acids and their encoded proteins and antibodies)

IT 160405-33-4P 161477-24-3P 161736-58-9P, Protein (human 233-amino acid) 169445-07-2P 183682-27-1P, Cellubrevin 2 (human clone 122826) 185229-04-3P 207353-75-1P 208668-41-1P 208668-48-8P 208668-49-9P 208668-57-9P 210165-58-5P 210167-80-9P 210478-13-0P, Receptor (human clone HTPEF86) 211304-23-3P, Membrane protein (human gene NHMP1) 212704-82-0P 212705-37-8P 212705-78-7P 212774-49-7P 212836-76-5P 212837-30-4P 212837-90-6P 212838-06-7P 212838-42-1P 212838-47-6P 212838-55-6P 213468-10-1P 213471-68-2P, Protein BBP (human heart Bak binding) 213826-65-4P 220104-93-8P, Protein DC3 (human dendritic

cells) 220239-21-4P 220483-85-2P 220705-63-5P 221369-70-6P 221369-74-0P 221877-49-2P 222536-56-3P 222614-91-7P 223607-53-2P 224301-63-7P 224564-82-3P 225372-08-7P 225372-14-5P 226934-74-3P 227289-57-8P 227792-85-0P 228249-96-5P 229477-09-2P 229486-90-2P 229965-62-2P 229965-63-3P 230288-83-2P 231285-13-5P 233674-74-3P 235087-94-2P 235088-03-6P 242462-91-5P 242463-31-6P 242795-93-3P 242795-95-5P 243122-35-2P 246034-21-9P 249560-68-7P, Protein SBHUNC50 (human) 249907-53-7P 249909-42-0P 250154-03-1P 250154-96-2P 250246-75-4P, Receptor (human Incyte clone 2132179) 250367-18-1P 251929-01-8P 251929-16-5P 251929-64-3P 251929-75-6P 251929-91-6P 252196-58-0P 252197-14-1P 252298-99-0P 252365-96-1P 252366-99-7P 253418-81-4P 253418-82-5P 253418-83-6P 253579-85-0P 255700-56-2P 255889-03-3P 255889-10-2P 255889-22-6P 256501-75-4P, Membrane protein (human gene C14orf1) 257259-23-7P 257854-53-8P 257854-56-1P 259161-25-6P 259163-54-7P 259163-78-5P 260535-23-7P 261345-75-9P 264867-37-0P 271231-71-1P, Mannosyltransferase (human gene Hmat-1) 271753-06-1P 271753-24-3P 280786-68-7P, Protein **ss3939** (human) 284690-25-1P 292889-88-4P, Protein (human gene YME1L) 294899-00-6P 296284-70-3P 299466-63-0P, Protein CGI-61 (human) 300424-58-2P 300596-32-1P 300601-48-3P 300609-42-1P 302873-46-7P 304029-28-5P 309763-61-9P 312542-13-5P 312655-45-1P 314016-49-4P 316925-26-5P 320644-28-8P 321453-17-2P 322014-56-2P 322485-59-6P 326627-73-0P 326833-56-1P 326837-07-4P, Protein (human clone NT2RM2001319) 326838-97-5P, Protein (human clone PLACE1009020) 326930-17-0P, Protein (human clone PLACE1009338) 326936-52-1P, Protein (human clone PLACE1001351) 326943-97-9P, Protein (human clone NT2RP3002033) 327111-80-8P, Protein (human clone NT2RM4001731) 330603-88-8P 335365-16-7P 339144-09-1P 339602-87-8P 339615-07-5P 340050-74-0P 340324-01-8P, Protein HSPC239 (human clone CBMAMB04) 340838-22-4P 341066-14-6P 343901-81-5P 343901-86-0P 343906-62-7P 344489-25-4P 344489-55-0P 352375-92-9P 352377-74-3P 352380-47-3P 352380-70-2P 352383-45-0P 352396-03-3P 352396-30-6P 352815-91-9P 352820-65-6P, Enzyme (human clone HELDW45 fragment) 355027-11-1P, Protein (human clone 787CIP2_123) 360154-33-2P 362068-78-8P 372205-06-6P 372539-77-0P 373393-35-2P, MS4A4A protein (human) 377094-08-1P, Protein (human clone HCFNH88) 377094-09-2DP, Protein (human clone HODDW37), qqq 377094-10-5P, Protein (human clone HPMFI38) 377094-11-6P, Protein (human clone HLTDP38) 377094-12-7P, Protein (human clone HMHBT30) 377094-13-8P, Protein (human clone HFCBA57) 377094-14-9P, Protein (human clone HSRAL33) 377094-15-0P, Protein (human clone HSSMQ84) 377094-16-1P, Protein (human clone HUKAB82) 377094-17-2P, Protein (human clone HDPPP46) 377094-18-3P, Protein (human clone HMTME11) 377094-19-4P, Protein (human clone HBMUK46) 377094-20-7P, Protein (human clone HETDT70) 377094-21-8P, Protein (human clone HMKAD85) 377094-22-9P, Protein (human clone HE9NE12) 377094-23-0P, Protein (human clone HE2AX73) 377094-24-1P, Protein (human clone HHGBV89) 377094-25-2P, Protein (human clone HTTDC06) 377094-26-3P, Protein (human clone HFXKR35) 377094-27-4P, Protein (human clone HHSDL85) 377094-28-5P, Protein (human clone HTECA32) 377094-29-6P, Protein (human clone HTEHL79) 377094-30-9P, Protein (human clone HPJBL54) 377094-31-0P, Protein (human clone HSDDD20) 377094-32-1P, Protein (human clone HCUCG74) 377094-33-2P, Protein (human clone HFIXK94) 377094-34-3P, Protein (human clone HPJAV46) 377094-35-4P, Protein (human clone HTTDL61) 377094-36-5P, Protein (human clone HFPBN94) 377094-37-6P, Protein (human clone HYBBG69) 377094-38-7P, Protein (human clone HDPOJ05) 377094-39-8P, Protein (human clone HMAGF64) 377094-40-1P, Protein (human clone HACCO38) 377094-41-2P, Protein (human clone HRAAM31) 377094-42-3P, Protein (human clone HWDAA03) 377094-43-4P, Protein (human clone HTHCV60) 377094-44-5P, Protein (human clone HTLEV17) 377094-45-6P, Protein (human

clone HCFAB91) 377094-46-7P, Protein (human clone HMWEE18) 377094-47-8P, Protein (human clone HTLAI85) 377094-48-9P, Protein (human clone HHPGQ38) 377094-49-0P, Protein (human clone HNGER82) 377094-50-3P, Protein (human clone HBJLU13) 377094-51-4P, Protein (human clone HCFDC55) 377094-52-5P, Protein (human clone HFKCT25) 377094-53-6P, Protein (human clone HAPOW05) 377094-54-7P, Protein (human clone HCUFP05) 377094-55-8P, Protein (human clone HE8CX53) 377094-56-9P, Protein (human clone HCENB31) 377094-57-0P, Protein (human clone H7TME55) 377094-58-1P, Protein (human clone HDHMA49) 377094-59-2P, Protein (human clone H BXBG68) 377094-60-5P, Protein (human clone H GBFC53) 377094-61-6P, Protein (human clone HPMCK47) 377094-62-7P, Protein (human clone HAPNX53) 377094-63-8P, Protein (human clone HOFAE02) 377094-64-9P, Protein (human clone HSLIQ83) 377094-65-0P, Protein (human clone HNTMD04) 377094-66-1P, Protein (human clone HRABY48) 377094-67-2P, Protein (human clone HDDAA17) 377094-68-3P, Protein (human clone HTRAC41) 377094-69-4P, Protein (human clone HOSCV06) 377094-70-7P, Protein (human clone HMCHS27) 377094-71-8P, Protein (human clone HEMFC09) 377094-72-9P, Protein (human clone HNTRJ16) 377094-73-0P, Protein (human clone HKAEJ09) 377094-74-1P, Protein (human clone HKMMS65) 377094-75-2P, Protein (human clone HNHGE09) 377094-76-3P, Protein (human clone HTTCT34) 377094-77-4P, Protein (human clone HBIAS14) 377094-78-5P, Protein (human clone HLHSC60) 377094-79-6P, Protein (human clone HKMAA36) 377094-80-9P, Protein (human clone HLTFA02) 377094-81-0P, Protein (human clone HSBBC07)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377094-82-1P, Protein (human clone HL2AE73) 377094-83-2P, Protein (human clone HE2OO57) 377094-84-3P, Protein (human clone HEEAR13) 377094-85-4P, Protein (human clone HFTYL13) 377094-86-5P, Protein (human clone HLWBH14) 377094-87-6P, Protein (human clone HATDW51) 377094-88-7P, Protein (human clone HDPWQ69) 377094-89-8P, Protein (human clone HNTBM67) 377094-90-1P, Protein (human clone HAIDY03) 377094-91-2P, Protein (human clone HDPDO12) 377094-92-3P, Protein (human clone HAGHC45) 377094-93-4P, Protein (human clone HNTNT65) 377094-94-5P, Protein (human clone HTTAA50) 377094-95-6P, Protein (human clone HAGBX32) 377094-96-7P, Protein (human clone HHTMM18) 377094-97-8P, Protein (human clone HHFGR08) 377094-98-9P, Protein (human clone HHBEU19) 377094-99-0P, Protein (human clone HWBBB21) 377095-00-6P, Protein (human clone HMMAV06) 377095-01-7P, Protein (human clone HISAM25) 377095-02-8P, Protein (human clone HRODX93) 377095-03-9P, Protein (human clone HCFMJ37) 377095-04-0P, Protein (human clone HMWAP17) 377095-05-1P, Protein (human clone HMCFA76) 377095-06-2P, Protein (human clone HTHCM28) 377095-07-3P, Protein (human clone HHEDB45) 377095-08-4P, Protein (human clone HTACX15) 377095-09-5P, Protein (human clone HFIZN55) 377095-10-8P, Protein (human clone HCE1U38) 377095-11-9P, Protein (human clone HNFIL36) 377095-12-0P, Protein (human clone HSKZB03) 377095-13-1P, Protein (human clone HNTMZ26) 377095-14-2P, Protein (human clone HNENC76) 377095-15-3P, Protein (human clone HHSGJ30) 377095-16-4P, Protein (human clone HJKSC77) 377095-17-5P, Protein (human clone HDABD32) 377095-18-6P, Protein (human clone HWACC64) 377095-19-7P, Protein (human clone HSDIJ72) 377095-20-0P, Protein (human clone HSLGO34) 377095-21-1P, Protein (human clone HTOJF39) 377095-22-2P, Protein (human clone HPDEF35) 377095-23-3P, Protein (human clone HFIAW95) 377095-24-4P, Protein (human clone HMEIU36) 377095-25-5P, Protein (human clone HHEDM89) 377095-26-6P, Protein (human clone HKABW60)

377095-27-7P, Protein (human clone HWLFB40) 377095-28-8P, Protein (human clone HDTDW40) 377095-29-9P, Protein (human clone HEAAK34) 377095-30-2P, Protein (human clone HLWAH41) 377095-31-3P, Protein (human clone HHSFI89) 377095-32-4P, Protein (human clone HSAVI33) 377095-33-5P, Protein (human clone HMJAX17) 377095-34-6P, Protein (human clone HLJDZ45) 377095-35-7P, Protein (human clone HAHBC57) 377095-36-8P, Protein (human clone HLYDR60) 377095-37-9P, Protein (human clone HCHMQ09) 377095-38-0P, Protein (human clone HADMD75) 377095-39-1P, Protein (human clone HKADW47) 377095-40-4P, Protein (human clone HFAUL30) 377095-41-5P, Protein (human clone HKADD23) 377095-42-6P, Protein (human clone HE8MO09) 377095-43-7P, Protein (human clone HE8FL67) 377095-44-8P, Protein (human clone HEOOA49) 377095-45-9P, Protein (human clone HMSJH49) 377095-46-0P, Protein (human clone HARAX45) 377095-47-1P, Protein (human clone HDTES50) 377095-48-2P, Protein (human clone HKGBC30) 377095-49-3P, Protein (human clone HKIXO37) 377095-50-6P, Protein (human clone HTLFI39) 377095-51-7P, Protein (human clone HEQBJ81) 377095-52-8P, Protein (human clone HAGES18) 377095-53-9P, Protein (human clone HHSGV20) 377095-54-0P, Protein (human clone HNECD55) 377095-55-1P, Protein (human clone HRAAO53) 377095-56-2P, Protein (human clone HDPGD34) 377095-57-3P, Protein (human clone HLYBU12) 377095-58-4P, Protein (human clone HEONV59) 377095-59-5P, Protein (human clone HCWHX54) 377095-60-8P, Protein (human clone HE8DF23) 377095-61-9P, Protein (human clone HOECO53) 377095-62-0P, Protein (human clone HDFAB91) 377095-63-1P, Protein (human clone HWLER32) 377095-64-2P, Protein (human clone HNFJE71) 377095-65-3P, Protein (human clone HOUHA56) 377095-66-4P, Protein (human clone HMSHT01) 377095-67-5P, Protein (human clone HAPQM57) 377095-68-6P, Protein (human clone HSLJK58) 377095-69-7P, Protein (human clone HSLHL67) 377095-70-0P, Protein (human clone HCEMF51) 377095-71-1P, Protein (human clone HTHCV59) 377095-72-2P, Protein (human clone HCHCI12) 377095-73-3P, Protein (human clone HOEAU34) 377095-74-4P, Protein (human clone HFASN59) 377095-75-5P, Protein (human clone HLHCU82) 377095-76-6P, Protein (human clone HSDJN50) 377095-77-7P, Protein (human clone HMAFM05) 377095-78-8P, Protein (human clone HKAAA18) 377095-79-9P, Protein (human clone HISCL61) 377095-80-2P, Protein (human clone HAGDA61) 377095-81-3P, Protein (human clone HFIIO11) 377095-82-4P, Protein (human clone HUUSGB32) 377095-83-5P, Protein (human clone HTXED15) 377095-84-6P, Protein (human clone HCFMF12) 377095-85-7P, Protein (human clone HSSJG62) 377095-86-8P, Protein (human clone HFIHF63) 377095-87-9P, Protein (human clone HMDAG54) 377095-88-0P, Protein (human clone HCHMI51) 377095-89-1P, Protein (human clone HAHEA63) 377095-90-4P, Protein (human clone HAJAN63) 377095-91-5P, Protein (human clone HSRFP52) 377095-92-6P, Protein (human clone HCHOH38) 377095-93-7P, Protein (human clone HMSBS61) 377095-94-8P, Protein (human clone HNFHK32) 377095-95-9P, Protein (human clone HTPCT63) 377095-96-0P, Protein (human clone HE8NL29) 377095-97-1P, Protein (human clone HTTFM66) 377095-98-2P, Protein (human clone HE9EM20) 377095-99-3P, Protein (human clone HISCQ44) 377096-00-9P, Protein (human clone HETAJ12) 377096-01-0P, Protein (human clone HDABX16) 377096-02-1P, Protein (human clone HFEBM11) 377096-03-2P, Protein (human clone HHGBS74) 377096-04-3P, Protein (human clone HTAAT39) 377096-05-4P, Protein (human clone HHSFO30) 377096-06-5P, Protein (human clone HTAFE69) 377096-07-6P, Protein (human clone HMSCM47) 377096-08-7P, Protein (human clone HETLM70) 377096-09-8P, Protein (human clone HLYEN32) 377096-10-1P, Protein (human clone HHFHU45) 377096-11-2P, Protein (human clone HHFHR59) 377096-12-3P, Protein (human clone HDPPA45) 377096-13-4P, Protein (human clone HMAGC74) 377096-14-5P, Protein (human clone HHFFR79) 377096-15-6P, Protein (human clone HMGBP83) 377096-16-7P, Protein (human clone HWBAQ71)

377096-17-8P, Protein (human clone HRACE71) 377096-18-9P, Protein (human clone HADGC71) 377096-19-0P, Protein (human clone HSXFL85) 377096-20-3P, Protein (human clone HNGDQ71) 377096-21-4P, Protein (human clone HTOJT28) 377096-22-5P, Protein (human clone HSDZF13) 377096-23-6P, Protein (human clone HTOBH39) 377096-24-7P, Protein (human clone HE9RP73) 377096-25-8P, Protein (human clone HSXDG07) 377096-26-9P, Protein (human clone HDPHG57) 377096-27-0P, Protein (human clone HGBAD15) 377096-28-1P, Protein (human clone HOEEP07) 377096-29-2P, Protein (human clone HFIHT50) 377096-30-5P, Protein (human clone HPMGQ75) 377096-31-6P, Protein (human clone HBJJH66) 377096-32-7P, Protein (human clone HEGBB78) 377096-33-8P, Protein (human clone HAJBC01) 377096-34-9P, Protein (human clone HHGCP75) 377096-35-0P, Protein (human clone HAIDO95) 377096-36-1P, Protein (human clone HE8UD19) 377096-37-2P, Protein (human clone HMAIT58) 377096-38-3P, Protein (human clone HDAAE77) 377096-39-4P, Protein (human clone HKAOJ07) 377096-40-7P, Protein (human clone HDTFC73) 377096-41-8P, Protein (human clone HDTFI32) 377096-42-9P, Protein (human clone HLQCY70) 377096-43-0P, Protein (human clone HELDG78) 377096-44-1P, Protein (human clone HAGEK19) 377096-45-2P, Protein (human clone H2CBA34) 377096-46-3P, Protein (human clone HDPTC79) 377096-47-4P, Protein (human clone HTHBY73) 377096-48-5P, Protein (human clone HE8DL19) 377096-49-6P, Protein (human clone HMEGE46) 377096-50-9P, Protein (human clone HTEIA85) 377096-51-0P, Protein (human clone HLYCQ80) 377096-52-1P, Protein (human clone HE2OF81) 377096-53-2P, Protein (human clone HTEBB88) 377096-54-3P, Protein (human clone HWHGD82) 377096-55-4P, Protein (human clone HWADH67) 377096-56-5P, Protein (human clone HKADC82) 377096-57-6P, Protein (human clone HHESK83) 377096-58-7P, Protein (human clone HMJAT16) 377096-59-8P, Protein (human clone HSLJK83) 377096-60-1P, Protein (human clone HADFW62) 377096-61-2P, Protein (human clone HDTBV64) 377096-62-3P, Protein (human clone HOHBR65) 377096-63-4P, Protein (human clone HRABZ84) 377096-64-5P, Protein (human clone HKABD18) 377096-65-6P, Protein (human clone HUFAJ06) 377096-66-7P, Protein (human clone HDQFV46) 377096-67-8P, Protein (human clone HMEKH64) 377096-68-9P, Protein (human clone HTLEE85) 377096-69-0P, Protein (human clone HCE4Q82) 377096-70-3P, Protein (human clone HODEC95) 377096-71-4P, Protein (human clone HCBBA47) 377096-72-5P, Protein (human clone HSKEQ61) 377096-73-6P, Protein (human clone HWEAC64) 377096-74-7P, Protein (human clone HSDFQ43) 377096-75-8P, Protein (human clone HMHBN86) 377096-76-9P, Protein (human clone HLTAZ78) 377096-77-0P, Protein (human clone HLDBM50) 377096-78-1P, Protein (human clone HHEDH33) 377096-79-2P, Protein (human clone HAIDL86) 377096-80-5P, Protein (human clone HTEPF14) 377096-81-6P, Protein (human clone HOEDD04) 377096-82-7P, Protein (human clone HODBK89) 377096-83-8P, Protein (human clone HMUAZ89) 377096-84-9P, Protein (human clone HSBBB92) 377096-85-0P, Protein (human clone HHBGJ75) 377096-86-1P, Protein (human clone HDPRY23) 377096-87-2P, Protein (human clone HBBBC20) 377096-88-3P, Protein (human clone HMELW08) 377096-89-4P, Protein (human clone HTPDL90) 377096-90-7P, Protein (human clone HTACZ08) 377096-91-8P, Protein (human clone HAGEC91) 377096-92-9P, Protein (human clone HTTCB23) 377096-93-0P, Protein (human clone HYAAL21) 377096-94-1P, Protein (human clone HTLHY91) 377096-95-2P, Protein (human clone HUTAD91) 377096-96-3P, Protein (human clone HKGDE58) 377096-97-4P, Protein (human clone HBIAW78) 377096-98-5P, Protein (human clone HTOIC11) 377096-99-6P, Protein (human clone HNTRM40) 377097-00-2P, Protein (human clone HSKAY30) 377097-01-3P, Protein (human clone HSSJN12) 377097-02-4P, Protein (human clone HTFBG93) 377097-03-5P, Protein (human clone HCHOO84) 377097-04-6P, Protein (human clone HE8OX93) 377097-05-7P, Protein (human clone HOFMV90) 377097-06-8P, Protein (human clone HTEFV95) 377097-07-9P,

Protein (human clone HETJA44) 377097-08-0P, Protein (human clone HE3DR93) 377097-09-1P, Protein (human clone HAJBT15) 377097-10-4P, Protein (human clone HDBAD63) 377097-11-5P, Protein (human clone HE8QH85) 377097-12-6P, Protein (human clone HAICU52) 377097-13-7P, Protein (human clone HE6BJ49)
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377097-14-8P, Protein (human clone HE8TJ39) 377097-15-9P, Protein (human clone HFTBG92) 377097-16-0P, Protein (human clone HDPBJ94) 377097-17-1P, Protein (human clone HPIAX11) 377097-18-2P, Protein (human clone HBGMW95) 377097-19-3P, Protein (human clone HUSIJ83) 377097-20-6P, Protein (human clone HBGDP38) 377097-21-7P, Protein (human clone HTXEC55) 377097-22-8P, Protein (human clone HFXGI63) 377097-23-9P, Protein (human clone HAMGW19) 377097-24-0P, Protein (human clone HSLDO85) 377097-25-1P, Protein (human clone HDQDF38) 377097-26-2P, Protein (human clone HULAW69) 377097-27-3P, Protein (human clone HE9QK23) 377097-28-4P, Protein (human clone HNTTB36) 377097-29-5P, Protein (human clone HETJG63) 377097-30-8P, Protein (human clone HFIDZ38) 377097-31-9P, Protein (human clone HLMDO95) 377097-32-0P, Protein (human clone HSLGA19) 377097-33-1P, Protein (human clone HGBGM53) 377097-34-2P, Protein (human clone HIBCO73) 377097-35-3P, Protein (human clone HDPOM13) 377097-36-4P, Protein (human clone HMEJR75) 377097-37-5P, Protein (human clone HOECE93) 377097-38-6P, Protein (human clone HLHGA65) 377097-39-7P, Protein (human clone HLKDC74) 377097-40-0P, Protein (human clone HDTAV81) 377097-41-1P, Protein (human clone HETIZ34) 377097-42-2P, Protein (human clone HDTJT12) 377097-43-3P, Protein (human clone HSVCA10) 377097-44-4P, Protein (human clone HDFQA53) 377097-45-5P, Protein (human clone HD9PC92) 377097-46-6P, Protein (human clone HMSOU92) 377097-47-7P, Protein (human clone HE8OX52) 377097-48-8P, Protein (human clone HDAAS81) 377097-49-9P, Protein (human clone HPRBB67) 377097-50-2P, Protein (human clone HPIBM51) 377097-51-3P, Protein (human clone HLYFY81) 377097-52-4P, Protein (human clone HDPLO68) 377097-53-5P, Protein (human clone HHEUU25) 377097-54-6P, Protein (human clone HNTBH70) 377097-55-7P, Protein (human clone HMIAN37) 377097-56-8P, Protein (human clone HPFDI25) 377097-57-9P, Protein (human clone HCUDM68) 377097-58-0P, Protein (human clone HCFCU33) 377097-59-1P, Protein (human clone HTGCM10) 377097-60-4P, Protein (human clone H2CBH25) 377097-61-5P, Protein (human clone HWLFQ55) 377097-62-6P, Protein (human clone HWLBK80) 377097-63-7P, Protein (human clone HWHQR45) 377097-64-8P, Protein (human clone HTTDO45) 377097-65-9P, Protein (human clone HRGDD63) 377097-66-0P, Protein (human clone HTNBX62) 377097-67-1P, Protein (human clone HLICA76) 377097-68-2P, Protein (human clone HAPOA59) 377097-69-3P, Protein (human clone HLMMX37) 377097-70-6P, Protein (human clone HWLHW64) 377097-71-7P, Protein (human clone HHERA41) 377097-72-8P, Protein (human clone HFXJT43) 377097-73-9P, Protein (human clone HE8CL14) 377097-74-0P, Protein (human clone HLWFJ59) 377097-75-1P, Protein (human clone HAJCQ05) 377097-76-2P, Protein (human clone HAGHC54) 377097-77-3P, Protein (human clone HULAY53) 377097-78-4P, Protein (human clone HD9DL48) 377097-79-5P, Protein (human clone HFKEH50) 377097-80-8P, Protein (human clone HUSXK49) 377097-81-9P, Protein (human clone HELHM15) 377097-82-0P, Protein (human clone HTEJP13) 377097-83-1P, Protein (human clone HDQHB46) 377097-84-2P, Protein (human clone HCETE50) 377097-85-3P, Protein (human clone HDTBO48) 377097-86-4P, Protein (human clone HODGL01) 377097-87-5P, Protein (human clone HE8TO35) 377097-88-6P, Protein (human clone HOHCB06)

377097-89-7P, Protein (human clone H2CBN10) 377097-90-0P, Protein (human clone HBJNB08) 377097-91-1P, Protein (human clone HHAMF80) 377097-92-2P, Protein (human clone HDPUR66) 377097-93-3P, Protein (human clone HBWBX66) 377097-94-4P, Protein (human clone HMHBR95) 377097-95-5P, Protein (human clone HEGAU68) 377097-96-6P, Protein (human clone HMEAD61) 377097-97-7P, Protein (human clone HDTDF94) 377097-98-8P, Protein (human clone HKAJL51) 377097-99-9P, Protein (human clone HODGZ47) 377098-00-5P, Protein (human clone HOHCE56) 377098-01-6P, Protein (human clone HSHCL04) 377098-02-7P, Protein (human clone HAJBR52) 377098-03-8P, Protein (human clone HSLEK65) 377098-04-9P, Protein (human clone HWGAF42) 377098-05-0P, Protein (human clone HOUEA63) 377098-06-1P, Protein (human clone HLWAW36) 377098-07-2P, Protein (human clone HDPHI63) 377098-08-3P, Protein (human clone HTEPM45) 377098-09-4P, Protein (human clone HTEBP06) 377098-10-7P, Protein (human clone HSKYK23) 377098-11-8P, Protein (human clone HBUAD85) 377098-12-9P, Protein (human clone HCEIN85) 377098-13-0P, Protein (human clone HROAX39) 377098-14-1P, Protein (human clone HHETF37) 377098-15-2P, Protein (human clone HKAAS52) 377098-16-3P, Protein (human clone HISES36) 377098-17-4P, Protein (human clone HTJMJ95) 377098-18-5P, Protein (human clone HTELT78) 377098-19-6P, Protein (human clone HHFBP51) 377098-20-9P, Protein (human clone HHBCS13) 377098-21-0P, Protein (human clone HAJAT72) 377098-22-1P, Protein (human clone HTLHK92) 377098-23-2P, Protein (human clone HAGBQ10) 377098-24-3P, Protein (human clone HCRBB73) 377098-25-4P, Protein (human clone HWHHU11) 377098-26-5P, Protein (human clone HRAEB76) 377098-27-6P, Protein (human clone HPJAO13) 377098-28-7P, Protein (human clone HHENF67) 377098-29-8P, Protein (human clone HLQDC55) 377098-30-1P, Protein (human clone HTTJW49) 377098-31-2P, Protein (human clone HSYAD28) 377098-32-3P, Protein (human clone HLWAR77) 377098-33-4P, Protein (human clone HCE2W33) 377098-34-5P, Protein (human clone HAJAV01) 377098-35-6P, Protein (human clone HWGQC67) 377098-36-7P, Protein (human clone HFIJC17) 377098-37-8P, Protein (human clone HBXCD74) 377098-38-9P, Protein (human clone HBGNJ21) 377098-39-0P, Protein (human clone HBGNW78) 377098-40-3P, Protein (human clone HSDZN36) 377098-41-4P, Protein (human clone HFPCS09) 377098-42-5P, Protein (human clone HAIBB95) 377098-43-6P, Protein (human clone HHEFI08) 377098-44-7P, Protein (human clone HE8OM63) 377098-45-8P, Protein (human clone HAJAG88) 377098-46-9P, Protein (human clone HAJCL92) 377098-47-0P, Protein (human clone HHAMA15) 377098-48-1P, Protein (human clone HPJDE45) 377098-49-2P, Protein (human clone HPMJG77) 377098-50-5P, Protein (human clone HFIHQ53) 377098-51-6P, Protein (human clone HUVFU38) 377098-52-7P, Protein (human clone HDPSB01) 377098-53-8P, Protein (human clone HKAPB61) 377098-54-9P, Protein (human clone HMEGF05) 377098-55-0P, Protein (human clone HPTVF17) 377098-56-1P, Protein (human clone HDLBF57) 377098-57-2P, Protein (human clone HE8QT62) 377098-58-3P, Protein (human clone HE9FI33) 377098-59-4P, Protein (human clone HOUBJ40) 377098-60-7P, Protein (human clone HHEVC06) 377098-61-8P, Protein (human clone HE8FS36) 377098-62-9P, Protein (human clone HE2SS47) 377098-63-0P, Protein (human clone HTELD06) 377098-64-1P, Protein (human clone HDPJH06) 377098-65-2P, Protein (human clone HDTKS69) 377098-66-3P, Protein (human clone HE6CH89) 377098-67-4P, Protein (human clone HDPGS20) 377098-68-5P, Protein (human clone HWBBZ12) 377098-69-6P, Protein (human clone HDPBI36) 377098-70-9P, Protein (human clone HMAEP64) 377098-71-0P, Protein (human clone HTYSK68) 377098-72-1P, Protein (human clone HDAAD50) 377098-73-2P, Protein (human clone HNTNC03) 377098-74-3P, Protein (human clone HCFNG65) 377098-75-4P, Protein (human clone HLMMI85) 377098-76-5P, Protein (human clone HBGMZ39) 377098-77-6P, Protein (human clone HNTNA78) 377098-78-7P, Protein (human clone HOVAN91)

377098-79-8P, Protein (human clone HLYER32) 377098-80-1P, Protein (human clone HFPEL47) 377098-81-2P, Protein (human clone HTPIJ41) 377098-82-3P, Protein (human clone HNTNC49) 377098-83-4P, Protein (human clone HLTCO94) 377098-84-5P, Protein (human clone HBIMT77) 377098-85-6P, Protein (human clone HTLIV70) 377098-86-7P, Protein (human clone HFADF33) 377098-87-8P, Protein (human clone HETJQ73) 377098-88-9P, Protein (human clone HAGGV44) 377098-89-0P, Protein (human clone HTTDM15) 377098-90-3P, Protein (human clone HADCY76) 377098-91-4P, Protein (human clone HDPXWS75) 377098-92-5P, Protein (human clone HMCDC50) 377098-93-6P, Protein (human clone HMADZ55) 377098-94-7P, Protein (human clone HTXNB76) 377098-95-8P, Protein (human clone HLWDD49) 377098-96-9P, Protein (human clone HLQGX48) 377098-97-0P, Protein (human clone HLQEF25) 377098-98-1P, Protein (human clone HTOHA37) 377098-99-2P, Protein (human clone HLHAW26) 377099-00-8P, Protein (human clone HKAAZ46) 377099-01-9P, Protein (human clone HAQAF12) 377099-02-0P, Protein (human clone HTXEX35) 377099-03-1P, Protein (human clone HE8TE64) 377099-04-2P, Protein (human clone HL3AC38) 377099-05-3P, Protein (human clone HMUAO31) 377099-06-4P, Protein (human clone HHAWD33) 377099-07-5P, Protein (human clone HTZMB08) 377099-08-6P, Protein (human clone HJBCE86) 377099-09-7P, Protein (human clone HFPCK56) 377099-10-0P, Protein (human clone HAPSP72) 377099-11-1P, Protein (human clone HACBM44) 377099-12-2P, Protein (human clone HLTEO24) 377099-13-3P, Protein (human clone HHFJP51) 377099-14-4P, Protein (human clone HHFLL87) 377099-15-5P, Protein (human clone HCUDR30) 377099-16-6P, Protein (human clone HHFHI24) 377099-17-7P, Protein (human clone HSIAI48) 377099-18-8P, Protein (human clone HHGBP47) 377099-19-9P, Protein (human clone HKADE35) 377099-20-2P, Protein (human clone HISCV20) 377099-21-3P, Protein (human clone HHEUE88) 377099-22-4P, Protein (human clone HHESR56) 377099-23-5P, Protein (human clone HHENU62) 377099-24-6P, Protein (human clone HE2RG38) 377099-25-7P, Protein (human clone HCEVS49) 377099-26-8P, Protein (human clone HKGBP90) 377099-27-9P, Protein (human clone HHFMX34) 377099-28-0P, Protein (human clone HOUED48) 377099-29-1P, Protein (human clone HHBBI26) 377099-30-4P, Protein (human clone HHAUZ72) 377099-31-5P, Protein (human clone HWMAM41) 377099-32-6P, Protein (human clone HCEOV70) 377099-33-7P, Protein (human clone HKGDL95) 377099-34-8P, Protein (human clone HCEGR84) 377099-35-9P, Protein (human clone HMIBL51) 377099-36-0P, Protein (human clone HFXJP30) 377099-37-1P, Protein (human clone HCHMP94) 377099-38-2P, Protein (human clone HOHBO69) 377099-39-3P, Protein (human clone HBJHY72) 377099-40-6P, Protein (human clone HWEAD78) 377099-41-7P, Protein (human clone HFIBK06) 377099-42-8P, Protein (human clone HE9RF77) 377099-43-9P, Protein (human clone HCEEU61) 377099-44-0P, Protein (human clone HOHBV41) 377099-45-1P, Protein (human clone HHFKC41)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377099-46-2P, Protein (human clone HOEMM23) 377099-47-3P, Protein (human clone HTXPN78) 377099-48-4P, Protein (human clone HFPGR87) 377099-49-5P, Protein (human clone HE8PR67) 377099-50-8P, Protein (human clone HDTDZ65) 377099-51-9P, Protein (human clone HWAEV63) 377099-52-0P, Protein (human clone HOHAV17) 377099-53-1P, Protein (human clone HNTCT36) 377099-54-2P, Protein (human clone HTPDM61) 377099-55-3P, Protein (human clone HTFOH87) 377099-56-4P, Protein (human clone HWBDQ32) 377099-57-5P, Protein (human clone HNHMC08) 377099-58-6P, Protein (human clone HE9QX59) 377099-59-7P, Protein (human clone HNFBU66) 377099-60-0P, Protein (human clone HLDQW16)

377099-61-1P, Protein (human clone HTLGS48) 377099-62-2P, Protein (human clone HNHDY54) 377099-63-3P, Protein (human clone HAPPS75) 377099-64-4P, Protein (human clone HWLEL47) 377099-65-5P, Protein (human clone HNGJG75) 377099-66-6P, Protein (human clone HKAJU40) 377099-67-7P, Protein (human clone HYABL83) 377099-68-8P, Protein (human clone HKADF82) 377099-69-9P, Protein (human clone HNGEK43) 377099-70-2P, Protein (human clone HTAJS93) 377099-71-3P, Protein (human clone HDPUM54) 377099-72-4P, Protein (human clone HMCHK65) 377099-73-5P, Protein (human clone HAIDK89) 377099-74-6P, Protein (human clone HTOHL88) 377099-75-7P, Protein (human clone HMEKU54) 377099-76-8P, Protein (human clone HOQBR51) 377099-77-9P, Protein (human clone HAMGP34) 377099-78-0P, Protein (human clone HDPTD75) 377099-79-1P, Protein (human clone HTLIC39) 377099-80-4P, Protein (human clone HNECI74) 377099-81-5P, Protein (human clone HCRNU23) 377099-82-6P, Protein (human clone HEEAF67) 377099-83-7P, Protein (human clone HWAFQ22) 377099-84-8P, Protein (human clone HCECR08) 377099-85-9P, Protein (human clone HDPCX59) 377099-86-0P, Protein (human clone HPJAV04) 377099-87-1P, Protein (human clone HHFMA59) 377099-88-2P, Protein (human clone HNTAI35) 377099-89-3P, Protein (human clone HCE3X63) 377099-90-6P, Protein (human clone HJPCG05) 377099-91-7P, Protein (human clone HOUFG48) 377099-92-8P, Protein (human clone HCYBG68) 377099-93-9P, Protein (human clone HDTBD83) 377099-94-0P, Protein (human clone HCDEG27) 377099-95-1P, Protein (human clone HBKDA80) 377099-96-2P, Protein (human clone HSSDP38) 377099-97-3P, Protein (human clone HSSGL44) 377099-98-4P, Protein (human clone HDODY10) 377099-99-5P, Protein (human clone HDFUB58) 377100-00-0P, Protein (human clone HSMBE70) 377100-01-1P, Protein (human clone HEPAA94) 377100-02-2P, Protein (human clone HHECU86) 377100-03-3P, Protein (human clone HBXGQ49) 377100-04-4P, Protein (human clone HUCOT09) 377100-05-5P, Protein (human clone HYBAF24) 377100-06-6P, Protein (human clone HFXJM86) 377100-07-7P, Protein (human clone HDTHL37) 377100-08-8P, Protein (human clone HBJFE32) 377100-09-9P, Protein (human clone HSLDY71) 377100-10-2P, Protein (human clone HULFN21) 377100-11-3P, Protein (human clone HCRPE50) 377100-12-4P, Protein (human clone HWDAF64) 377100-13-5P, Protein (human clone HBAGJ74) 377100-14-6P, Protein (human clone HT5EJ85) 377100-15-7P, Protein (human clone HKAKL77) 377100-16-8P, Protein (human clone HCFBY67) 377100-17-9P, Protein (human clone HUCNL85) 377100-18-0P, Protein (human clone HSDIW17) 377100-19-1P, Protein (human clone HHETS46) 377100-20-4P, Protein (human clone HAPSD53) 377100-21-5P, Protein (human clone HAMFW66) 377100-22-6P, Protein (human clone HTJMU48) 377100-23-7P, Protein (human clone HAUAE93) 377100-24-8P, Protein (human clone HAICK45) 377100-25-9P, Protein (human clone HAGHY26) 377100-26-0P, Protein (human clone HCLSJ87) 377100-27-1P, Protein (human clone HJBAQ50) 377100-28-2P, Protein (human clone HTELJ31) 377100-29-3P, Protein (human clone HPJBE61) 377100-30-6P, Protein (human clone HLTCU22) 377100-31-7P, Protein (human clone HE8DZ49) 377100-32-8P, Protein (human clone HEGAC86) 377100-33-9P, Protein (human clone HOUDS89) 377100-34-0P, Protein (human clone HCEVF41) 377100-35-1P, Protein (human clone HPWBO25) 377100-36-2P, Protein (human clone HSKNJ56) 377100-37-3P, Protein (human clone HSKJK72) 377100-38-4P, Protein (human clone HSDIS65) 377100-39-5P, Protein (human clone HHFEL55) 377100-40-8P, Protein (human clone HSIDL28) 377100-41-9P, Protein (human clone HELDT78) 377100-42-0P, Protein (human clone HCMTA51) 377100-43-1P, Protein (human clone HSAZG23) 377100-44-2P, Protein (human clone HATDH85) 377100-45-3P, Protein (human clone HTXNU58) 377100-46-4P, Protein (human clone HHSFI65) 377100-47-5P, Protein (human clone HRADG27) 377100-48-6P, Protein (human clone HWBCE30) 377100-49-7P, Protein (human clone HBGOF57) 377100-50-0P, Protein (human clone HAPNX79)

377100-51-1P, Protein (human clone HAJBZ74) 377100-52-2P, Protein (human clone HPMLG49) 377100-53-3P, Protein (human clone HPMJN59) 377100-54-4P, Protein (human clone HKAED76) 377100-55-5P, Protein (human clone HSPAD49) 377100-56-6P, Protein (human clone HARMV22) 377100-57-7P, Protein (human clone HSKIY76) 377100-58-8P, Protein (human clone HPJEV26) 377100-59-9P, Protein (human clone HPJEV91) 377100-60-2P, Protein (human clone HAMGK18) 377100-61-3P, Protein (human clone HCHOH94) 377100-62-4P, Protein (human clone HPJDA25) 377100-63-5P, Protein (human clone HJACF33) 377100-64-6P, Protein (human clone HHFMP57) 377100-65-7P, Protein (human clone HELGD39) 377100-66-8P, Protein (human clone HMKCV39) 377100-67-9P, Protein (human clone HNTOE45) 377100-68-0P, Protein (human clone HCUFV69) 377100-69-1P, Protein (human clone HMVCZ54) 377100-70-4P, Protein (human clone HMSHI94) 377100-71-5P, Protein (human clone HAPTE80) 377100-72-6P, Protein (human clone HSLJC72) 377100-73-7P, Protein (human clone HWBCR21) 377100-74-8P, Protein (human clone HKAAU27) 377100-75-9P, Protein (human clone HOSCJ09) 377100-76-0P, Protein (human clone HWBAE15) 377100-77-1P, Protein (human clone HWAFN46) 377100-78-2P, Protein (human clone HWAET91) 377100-79-3P, Protein (human clone HELHM41) 377100-80-6P, Protein (human clone HEQCA95) 377100-81-7P, Protein (human clone HAGEG94) 377100-82-8P, Protein (human clone HHFGM33) 377100-83-9P, Protein (human clone HTEQK83) 377100-84-0P, Protein (human clone HSBBS15) 377100-85-1P, Protein (human clone HS2IL80) 377100-86-2P, Protein (human clone HUSZB06) 377100-87-3P, Protein (human clone HUCNM83) 377100-88-4P, Protein (human clone HUCNW47) 377100-89-5P, Protein (human clone HEMGJ42) 377100-90-8P, Protein (human clone HUSYN11) 377100-91-9P, Protein (human clone HTADJ34) 377100-92-0P, Protein (human clone HTXPR30) 377100-93-1P, Protein (human clone HAHDP69) 377100-94-2P, Protein (human clone HTXBF16) 377100-95-3P, Protein (human clone HTXLG13) 377100-96-4P, Protein (human clone HTXHA69) 377100-97-5P, Protein (human clone HFTCV95) 377100-98-6P, Protein (human clone HTEHC92) 377100-99-7P, Protein (human clone HTFOL05) 377101-00-3P, Protein (human clone HTPDV70) 377101-01-4P, Protein (human clone HLYGH73) 377101-02-5P, Protein (human clone HCE3E13) 377101-03-6P, Protein (human clone HRAAH37) 377101-04-7P, Protein (human clone HTOFB26) 377101-05-8P, Protein (human clone HMELR15) 377101-06-9P, Protein (human clone HTLEI29) 377101-07-0P, Protein (human clone HTLGX79) 377101-08-1P, Protein (human clone HHFOV07) 377101-09-2P, Protein (human clone HTLDO59) 377101-10-5P, Protein (human clone HE8TM62) 377101-11-6P, Protein (human clone HJBCS70) 377101-12-7P, Protein (human clone HTFMP59) 377101-13-8P, Protein (human clone HTEOY86) 377101-14-9P, Protein (human clone HTEKC55) 377101-15-0P, Protein (human clone HTEPK69) 377101-16-1P, Protein (human clone HTENV57) 377101-17-2P, Protein (human clone HTEJF45) 377101-18-3P, Protein (human clone HTEGF16) 377101-19-4P, Protein (human clone HLTGU35) 377101-20-7P, Protein (human clone HTEDK07) 377101-21-8P, Protein (human clone HADGO63) 377101-22-9P, Protein (human clone HDPDO84) 377101-23-0P, Protein (human clone HNTAN11) 377101-24-1P, Protein (human clone HTTBJ31) 377101-25-2P, Protein (human clone HAMGO24) 377101-26-3P, Protein (human clone HODFK55) 377101-27-4P, Protein (human clone HBJMW49) 377101-28-5P, Protein (human clone HSXDF62) 377101-29-6P, Protein (human clone HSVCE22) 377101-30-9P, Protein (human clone HFKLC74) 377101-31-0P, Protein (human clone HTLEV30) 377101-32-1P, Protein (human clone HSRAV54) 377101-33-2P, Protein (human clone HTLID05) 377101-34-3P, Protein (human clone HWAGU62) 377101-35-4P, Protein (human clone HOEBN65) 377101-36-5P, Protein (human clone HOEEY60) 377101-37-6P, Protein (human clone HHECK12) 377101-38-7P, Protein (human clone HTLEM32) 377101-39-8P, Protein (human clone HPMUT61) 377101-40-1P, Protein (human clone HHEOI72) 377101-41-2P,

Protein (human clone HAPRN77) 377101-42-3P, Protein (human clone HLJDL43) 377101-43-4P, Protein (human clone HLJDU57) 377101-44-5P, Protein (human clone HHFKL03) 377101-45-6P, Protein (human clone HNTTB69) 377101-46-7P, Protein (human clone HKAAA37) 377101-47-8P, Protein (human clone HACCB78) 377101-48-9P, Protein (human clone HTLEO76) 377101-49-0P, Protein (human clone HTPBR76) 377101-50-3P, Protein (human clone HNTNH42) 377101-51-4P, Protein (human clone HFRCB84) 377101-52-5P, Protein (human clone HLWDZ48) 377101-53-6P, Protein (human clone HKAOC61) 377101-54-7P, Protein (human clone HHEMJ13) 377101-55-8P, Protein (human clone HTFOA36) 377101-56-9P, Protein (human clone HULEW22) 377101-57-0P, Protein (human clone HWADE54) 377101-58-1P, Protein (human clone HEMHH46) 377101-59-2P, Protein (human clone HFPIX46) 377101-60-5P, Protein (human clone HHPDK44) 377101-61-6P, Protein (human clone HE2FK85) 377101-62-7P, Protein (human clone HPQSL36) 377101-63-8P, Protein (human clone HEQBF64) 377101-64-9P, Protein (human clone HAMGB22) 377101-65-0P, Protein (human clone HDABD89) 377101-66-1P, Protein (human clone HPMFU11) 377101-67-2P, Protein (human clone HHEFL55) 377101-68-3P, Protein (human clone HHFJG66) 377101-69-4P, Protein (human clone HBMWZ85) 377101-70-7P, Protein (human clone HTTEL61) 377101-71-8P, Protein (human clone HHEKA25) 377101-72-9P, Protein (human clone HTLEH76) 377101-73-0P, Protein (human clone HHEVQ56) 377101-74-1P, Protein (human clone HTPHY39) 377101-75-2P, Protein (human clone HPCRR53) 377101-76-3P, Protein (human clone HLQEW26) 377101-77-4P, Protein (human clone HSLJR04)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377101-78-5P, Protein (human clone HCYBG26) 377101-79-6P, Protein (human clone HNGEZ52) 377101-80-9P, Protein (human clone H2LAY37) 377101-81-0P, Protein (human clone HCRND05) 377101-82-1P, Protein (human clone HCRNP66) 377101-83-2P, Protein (human clone HNTMD17) 377101-84-3P, Protein (human clone HMCGZ52) 377101-85-4P, Protein (human clone HOSOL09) 377101-86-5P, Protein (human clone HLQHJ48) 377101-87-6P, Protein (human clone HTTDU01) 377101-88-7P, Protein (human clone HOSMQ26) 377101-89-8P, Protein (human clone HMTME42) 377101-90-1P, Protein (human clone HRADL60) 377101-91-2P, Protein (human clone HWLMB55) 377101-92-3P, Protein (human clone HUSGZ51) 377101-93-4P, Protein (human clone HWDAN86) 377101-94-5P, Protein (human clone HFATS83) 377101-95-6P, Protein (human clone HBION06) 377101-96-7P, Protein (human clone HAPOO57) 377101-97-8P, Protein (human clone HCROG59) 377101-98-9P, Protein (human clone HDTBL01) 377101-99-0P, Protein (human clone HHFJY07) 377102-00-6P, Protein (human clone HOFMV44) 377102-01-7P, Protein (human clone HSLJN60) 377102-02-8P, Protein (human clone HWHGQ44) 377102-03-9P, Protein (human clone HCQDA63) 377102-04-0P, Protein (human clone HCFCS58) 377102-05-1P, Protein (human clone HWLMC49) 377102-06-2P, Protein (human clone HFCDF47) 377102-07-3P, Protein (human clone HCRNJ24) 377102-08-4P, Protein (human clone HCRNT27) 377102-09-5P, Protein (human clone HCQCC37) 377102-10-8P, Protein (human clone HFXKZ44) 377102-11-9P, Protein (human clone HWAAD15) 377102-12-0P, Protein (human clone HDABX38) 377102-13-1P, Protein (human clone HETJZ14) 377102-14-2P, Protein (human clone H2LAJ32) 377102-15-3P, Protein (human clone HTPIQ89) 377102-16-4P, Protein (human clone HTDAI12) 377102-17-5P, Protein (human clone HWLGV14) 377102-18-6P, Protein (human clone HCQBI31) 377102-19-7P, Protein (human clone HE9RM22) 377102-20-0P, Protein (human clone HBIUG54) 377102-21-1P, Protein (human clone HOBAE30) 377102-22-2P, Protein (human clone HEMHA04)

377102-23-3P, Protein (human clone HHEOX44) 377102-24-4P, Protein (human clone HWBBS84) 377102-25-5P, Protein (human clone HWLIP86) 377102-26-6P, Protein (human clone HSBAZ37) 377102-27-7P, Protein (human clone HOSXA83) 377102-28-8P, Protein (human clone HDQHQ51) 377102-29-9P, Protein (human clone HWAAB46) 377102-30-2P, Protein (human clone HOGDT09) 377102-31-3P, Protein (human clone HTEGT79) 377102-32-4P, Protein (human clone HOEJS41) 377102-33-5P, Protein (human clone HBXDI92) 377102-34-6P, Protein (human clone HHFMH12) 377102-35-7P, Protein (human clone HDPFP36) 377102-36-8P, Protein (human clone HDPWZ46) 377102-37-9P, Protein (human clone HFPBS73) 377102-38-0P, Protein (human clone HBBBE08) 377102-39-1P, Protein (human clone HNFIB64) 377102-40-4P, Protein (human clone HBJMN78) 377102-41-5P, Protein (human clone HHAUW81) 377102-42-6P, Protein (human clone HAUBB12) 377102-43-7P, Protein (human clone HFPHS77) 377102-44-8P, Protein (human clone HBGQN46) 377102-45-9P, Protein (human clone HTAFG29) 377102-46-0P, Protein (human clone HDPCT51) 377102-47-1P, Protein (human clone HMACZ08) 377102-48-2P, Protein (human clone HOHCA01) 377102-49-3P, Protein (human clone HTPEF72) 377102-50-6P, Protein (human clone HPHAB61) 377102-51-7P, Protein (human clone HTJNI73) 377102-52-8P, Protein (human clone HEOMO40) 377102-53-9P, Protein (human clone HBGQR89) 377102-54-0P, Protein (human clone HDPFT14) 377102-55-1P, Protein (human clone HNHFY67) 377102-56-2P, Protein (human clone HWLLR80) 377102-57-3P, Protein (human clone HLYAG35) 377102-58-4P, Protein (human clone HDPLU91) 377102-59-5P, Protein (human clone HDABG90) 377102-60-8P, Protein (human clone HDPQO40) 377102-61-9P, Protein (human clone HKAHL37) 377102-62-0P, Protein (human clone HBXAX11) 377102-63-1P, Protein (human clone HEEAG84) 377102-64-2P, Protein (human clone HE8PT01) 377102-65-3P, Protein (human clone HMVCG79) 377102-66-4P, Protein (human clone HSLJF33) 377102-67-5P, Protein (human clone HFKJI43) 377102-68-6P, Protein (human clone HFVHV40) 377102-69-7P, Protein (human clone HTXLR12) 377102-70-0P, Protein (human clone HDQEX68) 377102-71-1P, Protein (human clone HTPHG81) 377102-72-2P, Protein (human clone HETFJ66) 377102-73-3P, Protein (human clone HUVCM58) 377102-74-4P, Protein (human clone HDPGJ03) 377102-75-5P, Protein (human clone HWHHN55) 377102-76-6P, Protein (human clone HTTJH57) 377102-77-7P, Protein (human clone HMSNQ62) 377102-78-8P, Protein (human clone HGBHG78) 377102-79-9P, Protein (human clone HTLHJ08) 377102-80-2P, Protein (human clone HSIDI48) 377102-81-3P, Protein (human clone HRDDU37) 377102-82-4P, Protein (human clone HFLUI19) 377102-83-5P, Protein (human clone HTWAG66) 377102-84-6P, Protein (human clone HLCLE14) 377102-85-7P, Protein (human clone HOFMH52) 377102-86-8P, Protein (human clone HWAHE17) 377102-87-9P, Protein (human clone HWAEG32) 377102-88-0P, Protein (human clone HSLHB42) 377102-89-1P, Protein (human clone HDSAC28) 377102-90-4P, Protein (human clone HFIHT27) 377102-91-5P, Protein (human clone HBIMS61) 377102-92-6P, Protein (human clone HCDAH28) 377102-93-7P, Protein (human clone HSDFD90) 377102-94-8P, Protein (human clone HTLJK34) 377102-95-9P, Protein (human clone HNGKC65) 377102-96-0P, Protein (human clone HDPBD83) 377102-97-1P, Protein (human clone HHEVU86) 377102-98-2P, Protein (human clone HNFIB27) 377102-99-3P, Protein (human clone HAPSG46) 377103-00-9P, Protein (human clone HCWFW07) 377103-01-0P, Protein (human clone HUFCR29) 377103-02-1P, Protein (human clone HNTCN90) 377103-03-2P, Protein (human clone HCMSE07) 377103-04-3P, Protein (human clone HWMEV61) 377103-05-4P, Protein (human clone HDPWT82) 377103-06-5P, Protein (human clone HBGOU17) 377103-07-6P, Protein (human clone HETBT53) 377103-08-7P, Protein (human clone HRAEC49) 377103-09-8P, Protein (human clone HNHBD03) 377103-10-1P, Protein (human clone HTTCB17) 377103-11-2P, Protein (human clone HE9QG38) 377103-12-3P, Protein (human clone HTTJY18) 377103-13-4P,

Protein (human clone HPSND10) 377103-14-5P, Protein (human clone HDABX58) 377103-15-6P, Protein (human clone HDABX58) 377103-16-7P, Protein (human clone HELGM94) 377103-17-8P, Protein (human clone HJBBC09) 377103-18-9P, Protein (human clone HTXJF02) 377103-19-0P, Protein (human clone HKAEN78) 377103-20-3P, Protein (human clone HKADD76) 377103-21-4P, Protein (human clone HKIYF62) 377103-22-5P, Protein (human clone HDQDF85) 377103-23-6P, Protein (human clone HRAAA79) 377103-24-7P, Protein (human clone HFPAD41) 377103-25-8P, Protein (human clone HTAIV82) 377103-26-9P, Protein (human clone HACBW10) 377103-27-0P, Protein (human clone HUFBN79) 377103-28-1P, Protein (human clone HCFCN07) 377103-29-2P, Protein (human clone HLWDZ66) 377103-30-5P, Protein (human clone HEONP58) 377103-31-6P, Protein (human clone HMAGN19) 377103-32-7P, Protein (human clone HFCAP42) 377103-33-8P, Protein (human clone HWBBT49) 377103-34-9P, Protein (human clone HDPBT62) 377103-35-0P, Protein (human clone HWHHS59) 377103-36-1P, Protein (human clone HJPCP29) 377103-37-2P, Protein (human clone HHEBM09) 377103-38-3P, Protein (human clone HDPIV17) 377103-39-4P, Protein (human clone HBGNO49) 377103-40-7P, Protein (human clone HWAFQ40) 377103-41-8P, Protein (human clone HTLGZ03) 377103-42-9P, Protein (human clone HLYCX18) 377103-43-0P, Protein (human clone HSDEK82) 377103-44-1P, Protein (human clone HCEMU86) 377103-45-2P, Protein (human clone HEORN16) 377103-46-3P, Protein (human clone HKGBJ74) 377103-47-4P, Protein (human clone HOSPA48) 377103-48-5P, Protein (human clone HWHQN16) 377103-49-6P, Protein (human clone HFVIK60) 377103-50-9P, Protein (human clone HMAIH15) 377103-51-0P, Protein (human clone HTTDZ74) 377103-52-1P, Protein (human clone HUSGC38) 377103-53-2P, Protein (human clone HLHAN77) 377103-54-3P, Protein (human clone HFPKI70) 377103-55-4P, Protein (human clone HDRMD17) 377103-56-5P, Protein (human clone HEMDM16) 377103-57-6P, Protein (human clone HSLGA24) 377103-58-7P, Protein (human clone HMHBT84) 377103-59-8P, Protein (human clone HHEDW60) 377103-60-1P, Protein (human clone HNGNU93) 377103-61-2P, Protein (human clone HARMS29) 377103-62-3P, Protein (human clone HAMHH25) 377103-63-4P, Protein (human clone HLCLA47) 377103-64-5P, Protein (human clone HDPSO06) 377103-65-6P, Protein (human clone HFXKG51) 377103-66-7P, Protein (human clone HELEL31) 377103-67-8P, Protein (human clone HTLGQ83) 377103-68-9P, Protein (human clone HETJU23) 377103-69-0P, Protein (human clone HNGKB25) 377103-70-3P, Protein (human clone HADAM67) 377103-71-4P, Protein (human clone HDQPJ92) 377103-72-5P, Protein (human clone HHFFX31) 377103-73-6P, Protein (human clone HHESF39) 377103-74-7P, Protein (human clone HTLHB93) 377103-75-8P, Protein (human clone HDTJA78) 377103-76-9P, Protein (human clone HNGPL75) 377103-77-0P, Protein (human clone HNTDV93) 377103-78-1P, Protein (human clone HNSMB73) 377103-79-2P, Protein (human clone HTLGL03) 377103-80-5P, Protein (human clone HGBCN41) 377103-81-6P, Protein (human clone HWMBU89) 377103-82-7P, Protein (human clone HSEBA38) 377103-83-8P, Protein (human clone HEEAX26) 377103-84-9P, Protein (human clone HTLAG19) 377103-85-0P, Protein (human clone HISBV17) 377103-86-1P, Protein (human clone HFKLN07) 377103-87-2P, Protein (human clone HTLID36) 377103-88-3P, Protein (human clone HSLHV27) 377103-89-4P, Protein (human clone HSLJG70) 377103-90-7P, Protein (human clone HSFAK30) 377103-91-8P, Protein (human clone HTTBM62) 377103-92-9P, Protein (human clone HFCDT23) 377103-93-0P, Protein (human clone HDPGU86) 377103-94-1P, Protein (human clone H2CBE07) 377103-95-2P, Protein (human clone HTXLP33) 377103-96-3P, Protein (human clone HMEKG76) 377103-97-4P, Protein (human clone HTENG02) 377103-98-5P, Protein (human clone HTOAW80) 377103-99-6P, Protein (human clone HAJAW57) 377104-00-2P, Protein (human clone HTEHF89) 377104-01-3P, Protein (human clone HSYBB84) 377104-02-4P, Protein (human clone HTJMD30) 377104-03-5P,

Protein (human clone HELFG05) 377104-04-6P, Protein (human clone HHEHG38) 377104-05-7P, Protein (human clone HSLDT25) 377104-06-8P, Protein (human clone HSDGH19) 377104-07-9P, Protein (human clone HCEOU19) 377104-08-0P, Protein (human clone HBIMF04) 377104-09-1P, Protein (human clone HSKZE56)
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377104-10-4P, Protein (human clone HLJBD90) 377104-11-5P, Protein (human clone HAUAX28) 377104-12-6P, Protein (human clone HUCPU88) 377104-13-7P, Protein (human clone HFXKJ22) 377104-14-8P, Protein (human clone HWHPD05) 377104-15-9P, Protein (human clone HFRAN15) 377104-16-0P, Protein (human clone HHGCV39) 377104-17-1P, Protein (human clone HMAFM80) 377104-18-2P, Protein (human clone HAPOW71) 377104-19-3P, Protein (human clone HBCBW64) 377104-20-6P, Protein (human clone HBING74) 377104-21-7P, Protein (human clone HBIMJ94) 377104-22-8P, Protein (human clone HNHCI36) 377104-23-9P, Protein (human clone HAFAH26) 377104-24-0P, Protein (human clone HE8MV45) 377104-25-1P, Protein (human clone HUKEQ96) 377104-26-2P, Protein (human clone HKADF73) 377104-27-3P, Protein (human clone HSLEN72) 377104-28-4P, Protein (human clone HTPHK88) 377104-29-5P, Protein (human clone HDPFA53) 377104-30-8P, Protein (human clone HMSDQ93) 377104-31-9P, Protein (human clone HSXAD12) 377104-32-0P, Protein (human clone HWBAL42) 377104-33-1P, Protein (human clone HUJBO10) 377104-34-2P, Protein (human clone HMUAP06) 377104-35-3P, Protein (human clone HLYCA31) 377104-36-4P, Protein (human clone HETTY94) 377104-37-5P, Protein (human clone HMTAU01) 377104-38-6P, Protein (human clone HDPVO38) 377104-39-7P, Protein (human clone HSDKL35) 377104-40-0P, Protein (human clone HTLJA77) 377104-41-1P, Protein (human clone HCFLJ17) 377104-42-2P, Protein (human clone HNGKM74) 377104-43-3P, Protein (human clone HTTJQ27) 377104-44-4P, Protein (human clone HBCBF11) 377104-45-5P, Protein (human clone HFOYG86) 377104-46-6P, Protein (human clone HKGCJ92) 377104-47-7P, Protein (human clone HFPAB23) 377104-48-8P, Protein (human clone HWAGL92) 377104-49-9P, Protein (human clone HADME31) 377104-50-2P, Protein (human clone HEGBA84) 377104-51-3P, Protein (human clone HKLSC61) 377104-52-4P, Protein (human clone HEOMP62) 377104-53-5P, Protein (human clone HAMFN18) 377104-54-6P, Protein (human clone HWAEU20) 377104-55-7P, Protein (human clone HDPBG11) 377104-56-8P, Protein (human clone HWLEQ41) 377104-57-9P, Protein (human clone HTOIB37) 377104-58-0P, Protein (human clone HTGBM16) 377104-59-1P, Protein (human clone HOUGB95) 377104-60-4P, Protein (human clone HTELC21) 377104-61-5P, Protein (human clone HTPGV36) 377104-62-6P, Protein (human clone HFTDC58) 377104-63-7P, Protein (human clone HMUAG30) 377104-64-8P, Protein (human clone HCBME31) 377104-65-9P, Protein (human clone HDQDC13) 377104-66-0P, Protein (human clone HLHFX80) 377104-67-1P, Protein (human clone HOGBN93) 377104-68-2P, Protein (human clone HTPHE46) 377104-69-3P, Protein (human clone HTXQU08) 377104-70-6P, Protein (human clone HE8MU78) 377104-71-7P, Protein (human clone HTNBJ17) 377104-72-8P, Protein (human clone HTTJZ84) 377104-73-9P, Protein (human clone HLYBD96) 377104-74-0P, Protein (human clone HTTJT40) 377104-75-1P, Protein (human clone HETDR50) 377104-76-2P, Protein (human clone HDPRH64) 377104-77-3P, Protein (human clone HPIAN49) 377104-78-4P, Protein (human clone HDPVB49) 377104-79-5P, Protein (human clone HPJCP79) 377104-80-8P, Protein (human clone HHEVK59) 377104-81-9P, Protein (human clone HMKAK61) 377104-82-0P, Protein (human clone HWADM65) 377104-83-1P, Protein (human clone HLQFF81) 377104-84-2P, Protein (human clone HDPIG80)

377104-85-3P, Protein (human clone HUSID53) 377104-86-4P, Protein (human clone HDPFZ30) 377104-87-5P, Protein (human clone HE8CW35) 377104-88-6P, Protein (human clone HBHMH72) 377104-89-7P, Protein (human clone HLWAH05) 377104-90-0P, Protein (human clone HUJCH47) 377104-91-1P, Protein (human clone HDPCI84) 377104-92-2P, Protein (human clone HCRPU72) 377104-93-3P, Protein (human clone HFTCG52) 377104-94-4P, Protein (human clone HBINP48) 377104-95-5P, Protein (human clone HCQDE22) 377104-96-6P, Protein (human clone HDGCH22) 377104-97-7P, Protein (human clone HLWBY26) 377104-98-8P, Protein (human clone HKAHR43) 377104-99-9P, Protein (human clone HLDCE43) 377105-00-5P, Protein (human clone HFXKW18) 377105-01-6P, Protein (human clone HBGOJ26) 377105-02-7P, Protein (human clone HVVAL93) 377105-03-8P, Protein (human clone HHEDS40) 377105-04-9P, Protein (human clone HBMBF28) 377105-05-0P, Protein (human clone HJPAZ12) 377105-06-1P, Protein (human clone HISCV39) 377105-07-2P, Protein (human clone HPTVU91) 377105-08-3P, Protein (human clone HSLJD02) 377105-09-4P, Protein (human clone HNHOF94) 377105-10-7P, Protein (human clone H2CBM85) 377105-11-8P, Protein (human clone HTEME02) 377105-12-9P, Protein (human clone HCYAC03) 377105-13-0P, Protein (human clone HTTBH18) 377105-14-1P, Protein (human clone HOGBM94) 377105-15-2P, Protein (human clone HSLAS08) 377105-16-3P, Protein (human clone HTLJA52) 377105-17-4P, Protein (human clone HISCG60) 377105-18-5P, Protein (human clone HKAEK20) 377105-19-6P, Protein (human clone HDPVZ07) 377105-20-9P, Protein (human clone HCFBF02) 377105-21-0P, Protein (human clone HE8TB14) 377105-22-1P, Protein (human clone HHEFI15) 377105-23-2P, Protein (human clone HHEQF50) 377105-24-3P, Protein (human clone HOSAY56) 377105-25-4P, Protein (human clone HOGEA82) 377105-26-5P, Protein (human clone HHEJV91) 377105-27-6P, Protein (human clone HABAD39) 377105-28-7P, Protein (human clone HKAKC86) 377105-29-8P, Protein (human clone HUKEP18) 377105-30-1P, Protein (human clone HL2AE66) 377105-31-2P, Protein (human clone HHGDQ67) 377105-32-3P, Protein (human clone HHGJS83) 377105-33-4P, Protein (human clone HHFNI70) 377105-34-5P, Protein (human clone HNTAP78) 377105-35-6P, Protein (human clone HOGEN56) 377105-36-7P, Protein (human clone HWLOU33) 377105-37-8P, Protein (human clone HPMKP09) 377105-38-9P, Protein (human clone HDPKJ19) 377105-39-0P, Protein (human clone HOEJZ65) 377105-40-3P, Protein (human clone HHASY37) 377105-41-4P, Protein (human clone HBXBC08) 377105-42-5P, Protein (human clone HKIXQ06) 377105-43-6P, Protein (human clone HUFDB55) 377105-44-7P, Protein (human clone HAHCK43) 377105-45-8P, Protein (human clone HNSME80) 377105-46-9P, Protein (human clone HTXMM27) 377105-47-0P, Protein (human clone HTXPO61) 377105-48-1P, Protein (human clone HLWAM62) 377105-49-2P, Protein (human clone HFXLK46) 377105-50-5P, Protein (human clone HBMXK78) 377105-51-6P, Protein (human clone HMUAL57) 377105-52-7P, Protein (human clone HWCAD85) 377105-53-8P, Protein (human clone HHEXO15) 377105-54-9P, Protein (human clone HE8NI05) 377105-55-0P, Protein (human clone H2CBP53) 377105-56-1P, Protein (human clone HDPPP18) 377105-57-2P, Protein (human clone HSLFD86) 377105-58-3P, Protein (human clone HTLDD85) 377105-59-4P, Protein (human clone HDAAV92) 377105-60-7P, Protein (human clone HHEPR52) 377105-61-8P, Protein (human clone HSYDY88) 377105-62-9P, Protein (human clone HEOPR46) 377105-63-0P, Protein (human clone HDPIF47) 377105-64-1P, Protein (human clone HKAIP13) 377105-65-2P, Protein (human clone HTLIT05) 377105-66-3P, Protein (human clone HWLAJ33) 377105-67-4P, Protein (human clone HSKAS66) 377105-68-5P, Protein (human clone HOFNT25) 377105-69-6P, Protein (human clone HAABQ61) 377105-70-9P, Protein (human clone HFPFA83) 377105-71-0P, Protein (human clone HFIDN52) 377105-72-1P, Protein (human clone HHBEA82) 377105-73-2P, Protein (human clone HWHPC10) 377105-74-3P, Protein (human clone HDPXZ89)

377105-75-4P, Protein (human clone HLICA89) 377105-76-5P, Protein (human clone HTTDZ50) 377105-77-6P, Protein (human clone HTLHL43)
377105-78-7P, Protein (human clone HDQPN32) 377105-79-8P, Protein (human clone HOHBT28) 377105-80-1P, Protein (human clone HTPCP50)
377105-81-2P, Protein (human clone HWLCJ12) 377105-82-3P, Protein (human clone HTHCK88) 377105-83-4P, Protein (human clone HCE3M15)
377105-84-5P, Protein (human clone HSKGT01) 377105-85-6P, Protein (human clone HTAIJ50) 377105-86-7P, Protein (human clone HPJAS61)
377105-87-8P, Protein (human clone HTEKL48) 377105-88-9P, Protein (human clone HUVFI01) 377105-89-0P, Protein (human clone HHAOD94)
377105-90-3P, Protein (human clone HAGGF22) 377105-91-4P, Protein (human clone HTJMG26) 377105-92-5P, Protein (human clone HNTND88)
377105-93-6P, Protein (human clone HJABT11) 377105-94-7P, Protein (human clone HOUCY70) 377105-95-8P, Protein (human clone HNHCM07)
377105-96-9P, Protein (human clone HTAFC46) 377105-97-0P, Protein (human clone HRADL67) 377105-98-1P, Protein (human clone HCFCS40)
377105-99-2P, Protein (human clone HBINS69) 377106-00-8P, Protein (human clone HKGAO47) 377106-01-9P, Protein (human clone HMTBI19)
377106-02-0P, Protein (human clone HPMGN27) 377106-03-1P, Protein (human clone HWLEP57) 377106-04-2P, Protein (human clone HADGF57)
377106-05-3P, Protein (human clone HHEXO20) 377106-06-4P, Protein (human clone HWLGN53) 377106-07-5P, Protein (human clone HMIAH65)
377106-08-6P, Protein (human clone HWAAX38) 377106-09-7P, Protein (human clone HTJNG15) 377106-10-0P, Protein (human clone HSDJA72)
377106-11-1P, Protein (human clone HMCHF75) 377106-12-2P, Protein (human clone HDTAZ43) 377106-13-3P, Protein (human clone HAAAN55)
377106-14-4P, Protein (human clone HBODI05) 377106-15-5P, Protein (human clone HAJAH16) 377106-16-6P, Protein (human clone HOUDS09)
377106-17-7P, Protein (human clone HLWAF59) 377106-18-8P, Protein (human clone HCFNN18) 377106-19-9P, Protein (human clone HMSCR89)
377106-20-2P, Protein (human clone HDPCW53) 377106-21-3P, Protein (human clone HTOGI77) 377106-22-4P, Protein (human clone HAPBL13)
377106-23-5P, Protein (human clone HHEEN22) 377106-24-6P, Protein (human clone H2CBH75) 377106-25-7P, Protein (human clone HTLHU05)
377106-26-8P, Protein (human clone HDPPG85) 377106-27-9P, Protein (human clone HWMIB81) 377106-28-0P, Protein (human clone HHFJU87)
377106-29-1P, Protein (human clone HDHIB39) 377106-30-4P, Protein (human clone HTXSR92) 377106-31-5P, Protein (human clone HWEAD65)
377106-32-6P, Protein (human clone HUUAR12) 377106-33-7P, Protein (human clone HEMBT61) 377106-34-8P, Protein (human clone HNTCE17)
377106-35-9P, Protein (human clone HFFAV24) 377106-36-0P, Protein (human clone HEOPL36) 377106-37-1P, Protein (human clone HFKJM30)
377106-38-2P, Protein (human clone HTEPE35) 377106-39-3P, Protein (human clone HIBEG14) 377106-40-6P, Protein (human clone HIBCH43)
377106-41-7P, Protein (human clone HELDY60)
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377106-42-8P, Protein (human clone HDPRX11) 377106-43-9P, Protein (human clone HDPBN81) 377106-44-0P, Protein (human clone HSLJF08)
377106-45-1P, Protein (human clone HAGAE60) 377106-46-2P, Protein (human clone HTJNI49) 377106-47-3P, Protein (human clone HUFBA64)
377106-48-4P, Protein (human clone HSSAL39) 377106-49-5P, Protein (human clone HE8QR01) 377106-50-8P, Protein (human clone HLDQK77)
377106-51-9P, Protein (human clone HMSHP51) 377106-52-0P, Protein (human clone HJPBB56) 377106-53-1P, Protein (human clone HPWAS05)
377106-54-2P, Protein (human clone HUSIC81)
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,

unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 165475-99-0P 191434-95-4P 212773-87-0P 212836-28-7P 213252-94-9P
213254-36-5P 213254-40-1P 213822-24-3P 213822-74-3P 217304-49-9P
223910-90-5P 252351-38-5P 252364-49-1P 257853-72-8P 261343-79-7P
284689-61-8P 291580-59-1P 291786-20-4P 291788-87-9P 291789-02-1P
291789-07-6P 291791-80-5P 291794-25-7P 292090-67-6P 292096-92-5P
292097-04-2P 292097-81-5P 292098-02-3P 292187-90-7P 292188-28-4P
292188-81-9P 292645-10-4P 292645-45-5P 292645-48-8P 292645-67-1P
292647-08-6P 292647-44-0P 292647-75-7P 292647-83-7P 292648-16-9P
292648-52-3P 292650-40-9P 292876-72-3P 293332-27-1P 294683-87-7P
294906-25-5P 295373-34-1P 295376-89-5P 296965-17-8P 300426-87-3P
300619-52-7P 300871-69-6P 312651-54-0P 312778-91-9P 328596-42-5P
331880-86-5P 332086-67-6P 332087-00-0P 332430-48-5P 333460-94-9P
333461-94-2P 333462-51-4P 333462-59-2P 333462-86-5P 333463-43-7P
333463-72-2P 333464-31-6P 333464-50-9P 333464-95-2P 333464-96-3P
334026-84-5P 334027-12-2P 334027-17-7P 334027-73-5P 334028-65-8P
334030-55-6P 334031-10-6P 334031-58-2P 334031-59-3P 334031-75-3P
334032-33-6P 334032-39-2P 334032-77-8P 334032-89-2P 334032-95-0P
334033-50-0P 334034-37-6P 334034-58-1P 334034-63-8P 334034-68-3P
334035-08-4P 334035-30-2P 334035-58-4P 334041-59-7P 334042-30-7P
334042-35-2P 334043-98-0P 334045-32-8P 334045-35-1P 334045-65-7P
334045-71-5P 334045-77-1P 334045-87-3P 334045-91-9P 334046-03-6P
334046-08-1P 334046-25-2P 334046-75-2P 334046-96-7P 334047-00-6P
334047-03-9P 334047-13-1P 334047-18-6P 334047-19-7P 334047-25-5P
334047-28-8P 337542-30-0P 337986-67-1P 339139-75-2P 339140-39-5P
339143-36-1P 339215-91-7P 339216-04-5P 339605-51-5P 339605-64-0P
339608-97-8P 339611-10-8P 339613-56-8P 339613-59-1P 339613-69-3P
340050-17-1P 340837-91-4P 341065-71-2P 352395-48-3P 352589-80-1P
352730-25-7P 352730-85-9P 352737-03-2P 352802-14-3P 352804-39-8P
352812-01-2P 353530-04-8P 353530-98-0P 353545-06-9P 355466-91-0P
355469-32-8P 357226-22-3P 368491-91-2P 376398-19-5P 376398-20-8DP,
qqq 376398-21-9P 376398-22-0P 376398-23-1P 376398-24-2P
376398-25-3P 376398-26-4P 376398-27-5P 376398-28-6P 376398-29-7P
376398-30-0P 376398-31-1P 376398-32-2P 376398-33-3P 376398-34-4P
376398-35-5P 376398-36-6P 376398-37-7P 376398-38-8P 376398-39-9P
376398-40-2P 376398-41-3P 376398-42-4P 376398-43-5P 376398-44-6P
376398-45-7P 376398-46-8P 376398-47-9P 376398-48-0P 376398-49-1P
376398-50-4P 376398-51-5P 376398-52-6P 376398-53-7P 376398-54-8P
376398-55-9P 376398-56-0P 376398-57-1P 376398-58-2P 376398-59-3P
376398-60-6P 376398-61-7P 376398-62-8P 376398-63-9P 376398-64-0P
376398-65-1P 376398-66-2P 376398-67-3P 376398-68-4P 376398-69-5P
376398-70-8P 376398-71-9P 376398-72-0P 376398-73-1P 376398-74-2P
376398-75-3P 376398-76-4P 376398-77-5P 376398-78-6P 376398-79-7P
376398-80-0P 376398-81-1P 376398-82-2P 376398-83-3P 376398-84-4P
376398-85-5P 376398-86-6P 376398-87-7P 376398-88-8P 376398-89-9P
376398-90-2P 376398-91-3P 376398-92-4P 376398-93-5P 376398-94-6P
376398-95-7P 376398-96-8P 376398-97-9P 376398-98-0P 376398-99-1P
376399-00-7P 376399-01-8P 376399-02-9P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 376399-03-0P 376399-04-1P 376399-05-2P 376399-06-3P 376399-07-4P
376399-08-5P 376399-09-6P 376399-10-9P 376399-11-0P 376399-12-1P
376399-13-2P 376399-14-3P 376399-15-4P 376399-16-5P 376399-17-6P
376399-18-7P 376399-19-8P 376399-20-1P 376399-21-2P 376399-22-3P

376399-23-4P 376399-24-5P 376399-25-6P 376399-26-7P 376399-27-8P
376399-28-9P 376399-29-0P 376399-30-3P 376399-31-4P 376399-32-5P
376399-33-6P 376399-34-7P 376399-35-8P 376399-36-9P 376399-37-0P
376399-38-1P 376399-39-2P 376399-40-5P 376399-41-6P 376399-42-7P
376399-43-8P 376399-44-9P 376399-45-0P 376399-46-1P 376399-47-2P
376399-48-3P 376399-49-4P 376399-50-7P 376399-51-8P 376399-52-9P
376399-53-0P 376399-54-1P 376399-55-2P 376399-56-3P 376399-57-4P
376399-58-5P 376399-59-6P 376399-60-9P 376399-61-0P 376399-62-1P
376399-63-2P 376399-64-3P 376399-65-4P 376399-66-5P 376399-67-6P
376399-68-7P 376399-69-8P 376399-70-1P 376399-71-2P 376399-72-3P
376399-73-4P 376399-74-5P 376399-75-6P 376399-76-7P 376399-77-8P
376399-78-9P 376399-79-0P 376399-80-3P 376399-81-4P 376399-82-5P
376399-83-6P 376399-84-7P 376399-85-8P 376399-86-9P 376399-87-0P
376399-88-1P 376399-89-2P 376399-90-5P 376399-91-6P 376399-92-7P
376399-93-8P 376399-94-9P 376399-95-0P 376399-96-1P 376399-97-2P
376399-98-3P 376399-99-4P 376400-00-9P 376400-01-0P 376400-02-1P
376400-03-2P 376400-04-3P 376400-05-4P 376400-06-5P 376400-07-6P
376400-08-7P 376400-09-8P 376400-10-1P 376400-11-2P 376400-12-3P
376400-13-4P 376400-14-5P 376400-15-6P 376400-16-7P 376400-17-8P
376400-18-9P 376400-19-0P 376400-20-3P 376400-21-4P 376400-22-5P
376400-23-6P 376400-24-7P 376400-25-8P 376400-26-9P 376400-27-0P
376400-28-1P 376400-29-2P 376400-30-5P 376400-31-6P 376400-32-7P
376400-33-8P 376400-34-9P 376400-35-0P 376400-36-1P 376400-37-2P
376400-38-3P 376400-39-4P 376400-40-7P 376400-41-8P 376400-42-9P
376400-43-0P 376400-44-1P 376400-45-2P 376400-46-3P 376400-47-4P
376400-48-5P 376400-49-6P 376400-50-9P 376400-51-0P 376400-52-1P
376400-53-2P 376400-54-3P 376400-55-4P 376400-56-5P 376400-57-6P
376400-58-7P 376400-59-8P 376400-60-1P 376400-61-2P 376400-62-3P
376400-63-4P 376400-64-5P 376400-65-6P 376400-66-7P 376400-67-8P
376400-68-9P 376400-69-0P 376400-70-3P 376400-71-4P 376400-72-5P
376400-73-6P 376400-74-7P 376400-75-8P 376400-76-9P 376400-77-0P
376400-78-1P 376400-79-2P 376400-80-5P 376400-81-6P 376400-82-7P
376400-83-8P 376400-84-9P 376400-85-0P 376400-86-1P 376400-87-2P
376400-88-3P 376400-89-4P 376400-90-7P 376400-91-8P 376400-92-9P
376400-93-0P 376400-94-1P 376400-95-2P 376400-96-3P 376400-97-4P
376400-98-5P 376400-99-6P 376401-00-2P 376401-01-3P 376401-02-4P
376401-03-5P 376401-04-6P 376401-05-7P 376401-06-8P 376401-07-9P
376401-08-0P 376401-09-1P 376401-10-4P 376401-11-5P 376401-12-6P
376401-13-7P 376401-14-8P 376401-15-9P 376401-16-0P 376401-17-1P
376401-18-2P 376401-19-3P 376401-20-6P 376401-21-7P 376401-22-8P
376401-23-9P 376401-24-0P 376401-25-1P 376401-26-2P 376401-27-3P
376401-28-4P 376401-29-5P 376401-30-8P 376401-31-9P 376401-32-0P
376401-33-1P 376401-34-2P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 376401-35-3P 376401-36-4P 376401-37-5P 376401-38-6P 376401-39-7P
376401-40-0P 376401-41-1P 376401-42-2P 376401-43-3P 376401-44-4P
376401-45-5P 376401-46-6P 376401-47-7P 376401-48-8P 376401-49-9P
376401-50-2P 376401-51-3P 376401-52-4P 376401-53-5P 376401-54-6P
376401-55-7P 376401-56-8P 376401-57-9P 376401-58-0P 376401-59-1P
376401-60-4P 376401-61-5P 376401-62-6P 376401-63-7P 376401-64-8P
376401-65-9P 376401-66-0P 376401-67-1P 376401-68-2P 376401-69-3P
376401-70-6P 376401-71-7P 376401-72-8P 376401-73-9P 376401-74-0P
376401-75-1P 376401-76-2P 376401-77-3P 376401-78-4P 376401-79-5P
376401-80-8P 376401-81-9P 376401-82-0P 376401-83-1P 376401-84-2P
376401-85-3P 376401-86-4P 376401-87-5P 376401-88-6P 376401-89-7P
376401-90-0P 376401-91-1P 376401-92-2P 376401-93-3P 376401-94-4P

376401-95-5P 376401-96-6P 376401-97-7P 376401-98-8P 376401-99-9P
376402-00-5P 376402-01-6P 376402-02-7P 376402-03-8P 376402-04-9P
376402-05-0P 376402-06-1P 376402-07-2P 376402-08-3P 376402-09-4P
376402-10-7P 376402-11-8P 376402-12-9P 376402-13-0P 376402-14-1P
376402-15-2P 376402-16-3P 376402-17-4P 376402-18-5P 376402-19-6P
376402-20-9P 376402-21-0P 376402-22-1P 376402-23-2P 376402-24-3P
376402-25-4P 376402-26-5P 376402-27-6P 376402-28-7P 376402-29-8P
376402-30-1P 376402-31-2P 376402-32-3P 376402-33-4P 376402-34-5P
376402-35-6P 376402-36-7P 376402-37-8P 376402-38-9P 376402-39-0P
376402-40-3P 376402-41-4P 376402-42-5P 376402-43-6P 376402-44-7P
376402-45-8P 376402-46-9P 376402-47-0P 376402-48-1P 376402-49-2P
376402-50-5P 376402-51-6P 376402-52-7P 376402-53-8P 376402-54-9P
376402-55-0P 376402-56-1P 376402-57-2P 376402-58-3P 376402-59-4P
376402-60-7P 376402-61-8P 376402-62-9P 376402-63-0P 376402-64-1P
376402-65-2P 376402-66-3P 376402-67-4P 376402-68-5P 376402-69-6P
376402-70-9P 376402-71-0P 376402-72-1P 376402-73-2P 376402-74-3P
376402-75-4P 376402-76-5P 376402-77-6P 376402-78-7P 376402-79-8P
376402-80-1P 376402-81-2P 376402-82-3P 376402-83-4P 376402-84-5P
376402-85-6P 376402-86-7P 376402-87-8P 376402-88-9P 376402-89-0P
376402-90-3P 376402-91-4P 376402-92-5P 376402-93-6P 376402-94-7P
376402-95-8P 376402-96-9P 376402-97-0P 376402-98-1P 376402-99-2P
376403-00-8P 376403-01-9P 376403-02-0P 376403-03-1P 376403-04-2P
376403-05-3P 376403-06-4P 376403-07-5P 376403-08-6P 376403-09-7P
376403-10-0P 376403-11-1P 376403-12-2P 376403-13-3P 376403-14-4P
376403-15-5P 376403-16-6P 376403-17-7P 376403-18-8P 376403-19-9P
376403-20-2P 376403-21-3P 376403-22-4P 376403-23-5P 376403-24-6P
376403-25-7P 376403-26-8P 376403-27-9P 376403-28-0P 376403-29-1P
376403-30-4P 376403-31-5P 376403-32-6P 376403-33-7P 376403-34-8P
376403-35-9P 376403-36-0P 376403-37-1P 376403-38-2P 376403-39-3P
376403-40-6P 376403-41-7P 376403-42-8P 376403-43-9P 376403-44-0P
376403-45-1P 376403-46-2P 376403-47-3P 376403-48-4P 376403-49-5P
376403-50-8P 376403-51-9P 376403-52-0P 376403-53-1P 376403-54-2P
376403-55-3P 376403-56-4P 376403-57-5P 376403-58-6P 376403-59-7P
376403-60-0P 376403-61-1P 376403-62-2P 376403-63-3P 376403-64-4P
376403-65-5P 376403-66-6P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 376403-67-7P 376403-68-8P 376403-69-9P 376403-70-2P 376403-71-3P
376403-72-4P 376403-73-5P 376403-74-6P 376403-75-7P 376403-76-8P
376403-77-9P 376403-78-0P 376403-79-1P 376403-80-4P 376403-81-5P
376403-82-6P 376403-83-7P 376403-84-8P 376403-85-9P 376403-86-0P
376403-87-1P 376403-88-2P 376403-89-3P 376403-90-6P 376403-91-7P
376403-92-8P 376403-93-9P 376403-94-0P 376403-95-1P 376403-96-2P
376403-97-3P 376403-98-4P 376403-99-5P 376404-00-1P 376404-01-2P
376404-02-3P 376404-03-4P 376404-04-5P 376404-05-6P 376404-06-7P
376404-07-8P 376404-08-9P 376404-09-0P 376404-10-3P 376404-11-4P
376404-12-5P 376404-13-6P 376404-14-7P 376404-15-8P 376404-16-9P
376404-17-0P 376404-18-1P 376404-19-2P 376404-20-5P 376404-21-6P
376404-22-7P 376404-23-8P 376404-24-9P 376404-25-0P 376404-26-1P
376404-27-2P 376404-28-3P 376404-29-4P 376404-30-7P 376404-31-8P
376404-32-9P 376404-33-0P 376404-34-1P 376404-35-2P 376404-36-3P
376404-37-4P 376404-38-5P 376404-39-6P 376404-40-9P 376404-41-0P
376404-42-1P 376404-43-2P 376404-44-3P 376404-45-4P 376404-46-5P
376404-47-6P 376404-48-7P 376404-49-8P 376404-50-1P 376404-51-2P
376404-52-3P 376404-53-4P 376404-54-5P 376404-55-6P 376404-56-7P
376404-57-8P 376404-58-9P 376404-59-0P 376404-60-3P 376404-61-4P
376404-62-5P 376404-63-6P 376404-64-7P 376404-65-8P 376404-66-9P

376404-67-0P 376404-68-1P 376404-69-2P 376404-70-5P 376404-71-6P
376404-72-7P 376404-73-8P 376404-74-9P 376404-75-0P 376404-76-1P
376404-77-2P 376404-78-3P 376404-79-4P 376404-80-7P 376404-81-8P
376404-82-9P 376404-83-0P 376404-84-1P 376404-85-2P 376404-86-3P
376404-87-4P 376404-88-5P 376404-89-6P 376404-90-9P 376404-91-0P
376404-92-1P 376404-93-2P 376404-94-3P 376404-95-4P 376404-96-5P
376404-97-6P 376404-98-7P 376404-99-8P 376405-00-4P 376405-01-5P
376405-02-6P 376405-03-7P 376405-04-8P 376405-05-9P 376405-06-0P
376405-07-1P 376405-08-2P 376405-09-3P 376405-10-6P 376405-11-7P
376405-12-8P 376405-13-9P 376405-14-0P 376405-15-1P 376405-16-2P
376405-17-3P 376405-18-4P 376405-19-5P 376405-20-8P 376405-21-9P
376405-22-0P 376405-23-1P 376405-24-2P 376405-25-3P 376405-26-4P
376405-27-5P 376405-28-6P 376405-29-7P 376405-30-0P 376405-31-1P
376405-32-2P 376405-33-3P 376405-34-4P 376405-35-5P 376405-36-6P
376405-37-7P 376405-38-8P 376405-39-9P 376405-40-2P 376405-41-3P
376405-42-4P 376405-43-5P 376405-44-6P 376405-45-7P 376405-46-8P
376405-47-9P 376405-48-0P 376405-49-1P 376405-50-4P 376405-51-5P
376405-52-6P 376405-53-7P 376405-54-8P 376405-55-9P 376405-56-0P
376405-57-1P 376405-58-2P 376405-59-3P 376405-60-6P 376405-61-7P
376405-62-8P 376405-63-9P 376405-64-0P 376405-65-1P 376405-66-2P
376405-67-3P 376405-68-4P 376405-69-5P 376405-70-8P 376405-71-9P
376405-72-0P 376405-73-1P 376405-74-2P 376405-75-3P 376405-76-4P
376405-77-5P 376405-78-6P 376405-79-7P 376405-80-0P 376405-81-1P
376405-82-2P 376405-83-3P 376405-84-4P 376405-85-5P 376405-86-6P
376405-87-7P 376405-88-8P 376405-89-9P 376405-90-2P 376405-91-3P
376405-92-4P 376405-93-5P 376405-94-6P 376405-95-7P 376405-96-8P
376405-97-9P 376405-98-0P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 376405-99-1P 376406-00-7P 376406-01-8P 376406-02-9P 376406-03-0P
376406-04-1P 376406-05-2P 376406-06-3P 376406-07-4P 376406-08-5P
376406-09-6P 376406-10-9P 376406-11-0P 376406-12-1P 376406-13-2P
376406-14-3P 376406-15-4P 376406-16-5P 376406-17-6P 376406-18-7P
376406-19-8P 376406-20-1P 376406-21-2P 376406-22-3P 376406-23-4P
376406-24-5P 376406-25-6P 376406-26-7P 376406-27-8P 376406-28-9P
376406-29-0P 376406-30-3P 376406-31-4P 376406-32-5P 376406-33-6P
376406-34-7P 376406-35-8P 376406-36-9P 376406-37-0P 376406-38-1P
376406-39-2P 376406-40-5P 376406-41-6P 376406-42-7P 376406-43-8P
376406-44-9P 376406-45-0P 376406-46-1P 376406-47-2P 376406-48-3P
376406-49-4P 376406-50-7P 376406-51-8P 376406-52-9P 376406-53-0P
376406-54-1P 376406-55-2P 376406-56-3P 376406-57-4P 376406-58-5P
376406-59-6P 376406-60-9P 376406-61-0P 376406-62-1P 376406-63-2P
376406-64-3P 376406-65-4P 376406-66-5P 376406-67-6P 376406-68-7P
376406-69-8P 376406-70-1P 376406-71-2P 376406-72-3P 376406-73-4P
376406-74-5P 376406-75-6P 376406-76-7P 376406-77-8P 376406-78-9P
376406-79-0P 376406-80-3P 376406-81-4P 376406-82-5P 376406-83-6P
376406-84-7P 376406-85-8P 376406-86-9P 376406-87-0P 376406-88-1P
376406-89-2P 376406-90-5P 376406-91-6P 376406-92-7P 376406-93-8P
376406-94-9P 376406-95-0P 376406-96-1P 376406-97-2P 376406-98-3P
376406-99-4P 376407-00-0P 376407-01-1P 376407-02-2P 376407-03-3P
376407-04-4P 376407-05-5P 376407-06-6P 376407-07-7P 376407-08-8P
376407-09-9P 376407-10-2P 376407-11-3P 376407-12-4P 376407-13-5P
376407-14-6P 376407-15-7P 376407-16-8P 376407-17-9P 376407-18-0P
376407-19-1P 376407-20-4P 376407-21-5P 376407-22-6P 376407-23-7P
376407-24-8P 376407-25-9P 376407-26-0P 376407-27-1P 376407-28-2P
376407-29-3P 376407-30-6P 376407-31-7P 376407-32-8P 376407-33-9P
376407-34-0P 376407-35-1P 376407-36-2P 376407-37-3P 376407-38-4P

376407-39-5P 376407-40-8P 376407-41-9P 376407-42-0P 376407-43-1P
376407-44-2P 376407-45-3P 376407-46-4P 376407-47-5P 376407-48-6P
376407-49-7P 376407-50-0P 376407-51-1P 376407-52-2P 376407-53-3P
376407-54-4P 376407-55-5P 376407-56-6P 376407-57-7P 376407-58-8P
376407-59-9P 376407-60-2P 376407-61-3P 376407-62-4P 376407-63-5P
376407-64-6P 376407-65-7P 376407-66-8P 376407-67-9P 376407-68-0P
376407-69-1P 376407-70-4P 376407-71-5P 376407-72-6P 376407-73-7P
376407-74-8P 376407-75-9P 376407-76-0P 376407-77-1P 376407-78-2P
376407-79-3P 376407-80-6P 376407-81-7P 376407-82-8P 376407-83-9P
376407-84-0P 376407-85-1P 376407-86-2P 376407-87-3P 376407-88-4P
376407-89-5P 376407-90-8P 376407-91-9P 376407-92-0P 376407-93-1P
376407-94-2P 376407-95-3P 376407-96-4P 376407-97-5P 376407-98-6P
376407-99-7P 376408-00-3P 376408-01-4P 376408-02-5P 376408-03-6P
376408-04-7P 376408-05-8P 376408-06-9P 376408-07-0P 376408-08-1P
376408-09-2P 376408-10-5P 376408-11-6P 376408-12-7P 376408-13-8P
376408-14-9P 376408-15-0P 376408-16-1P 376408-17-2P 376408-18-3P
376408-19-4P 376408-20-7P 376408-21-8P 376408-22-9P 376408-23-0P
376408-24-1P 376408-25-2P 376408-26-3P 376408-27-4P 376408-28-5P
376408-29-6P 376408-30-9P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 376408-31-0P 376408-32-1P 376408-33-2P 376408-34-3P 376408-35-4P
376408-36-5P 376408-37-6P 376408-38-7P 376408-39-8P 376408-40-1P
376408-41-2P 376408-42-3P 376408-43-4P 376408-44-5P 376408-45-6P
376408-46-7P 376408-47-8P 376408-48-9P 376408-49-0P 376408-50-3P
376408-51-4P 376408-52-5P 376408-53-6P 376408-54-7P 376408-55-8P
376408-56-9P 376408-57-0P 376408-58-1P 376408-59-2P 376408-60-5P
376408-61-6P 376408-62-7P 376408-63-8P 376408-64-9P 376408-65-0P
376408-66-1P 376408-67-2P 376408-68-3P 376408-69-4P 376408-70-7P
376408-71-8P 376408-72-9P 376408-73-0P 376408-74-1P 376408-75-2P
376408-76-3P 376408-77-4P 376408-78-5P 376408-79-6P 376408-80-9P
376408-81-0P 376408-82-1P 376408-83-2P 376408-84-3P 376408-85-4P
376408-86-5P 376408-87-6P 376408-88-7P 376408-89-8P 376408-90-1P
376408-91-2P 376408-92-3P 376408-93-4P 376408-94-5P 376408-95-6P
376408-96-7P 376408-97-8P 376408-98-9P 376408-99-0P 376409-00-6P
376409-01-7P 376409-02-8P 376409-03-9P 376409-04-0P 376409-05-1P
376409-06-2P 376409-07-3P 376409-08-4P 376409-09-5P 376409-10-8P
376409-11-9P 376409-12-0P 376409-13-1P 376409-14-2P 376409-15-3P
376409-16-4P 376409-17-5P 376409-18-6P 376409-19-7P 376409-20-0P
376409-21-1P 376409-22-2P 376409-23-3P 376409-24-4P 376409-25-5P
376409-26-6P 376409-27-7P 376409-28-8P 376409-29-9P 376409-30-2P
376409-31-3P 376409-32-4P 376409-33-5P 376409-34-6P 376409-35-7P
376409-36-8P 376409-37-9P 376409-38-0P 376409-39-1P 376409-40-4P
376409-41-5P 376409-42-6P 376409-43-7P 376409-44-8P 376409-45-9P
376409-46-0P 376409-47-1P 376409-48-2P 376409-49-3P 376409-50-6P
376409-51-7P 376409-52-8P 376409-53-9P 376409-54-0P 376409-55-1P
376409-56-2P 376409-57-3P 376409-58-4P 376409-59-5P 376409-60-8P
376409-61-9P 376409-62-0P 376409-63-1P 376409-64-2P 376409-65-3P
376409-66-4P 376409-67-5P 376409-68-6P 376409-69-7P 376409-70-0P
376409-71-1P 376409-72-2P 376409-73-3P 376409-74-4P 376409-75-5P
376409-76-6P 376409-77-7P 376409-78-8P 376409-79-9P 376409-80-2P
376409-81-3P 376409-82-4P 376409-83-5P 376409-84-6P 376409-85-7P
376409-86-8P 376409-87-9P 376409-88-0P 376409-89-1P 376409-90-4P
376409-91-5P 376409-92-6P 376409-93-7P 376409-94-8P 376409-95-9P
376409-96-0P 376409-97-1P 376409-98-2P 376409-99-3P 376410-00-3P
376410-01-4P 376410-02-5P 376410-03-6P 376410-04-7P 376410-05-8P
376410-06-9P 376410-07-0P 376410-08-1P 376410-09-2P 376410-10-5P

376410-11-6P 376410-12-7P 376410-13-8P 376410-14-9P 376410-15-0P
376410-16-1P 376410-17-2P 376410-18-3P 376410-19-4P 376410-20-7P
376410-21-8P 376410-22-9P 376410-23-0P 376410-24-1P 376410-25-2P
376410-26-3P 376410-27-4P 376410-28-5P 376410-29-6P 376410-30-9P
376410-31-0P 376410-32-1P 376410-33-2P 376410-34-3P 376410-35-4P
376410-36-5P 376410-37-6P 376410-38-7P 376410-39-8P 376410-40-1P
376410-41-2P 376410-42-3P 376410-43-4P 376410-44-5P 376410-45-6P
376410-46-7P 376410-47-8P 376410-48-9P 376410-49-0P 376410-50-3P
376410-51-4P 376410-52-5P 376410-53-6P 376410-54-7P 376410-55-8P
376410-56-9P 376410-57-0P 376410-58-1P 376410-59-2P 376410-60-5P
376410-61-6P 376410-62-7P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 376410-63-8P 376410-64-9P 376410-65-0P 376410-66-1P 376410-67-2P
376410-68-3P 376410-69-4P 376410-70-7P 376410-71-8P 376410-72-9P
376410-73-0P 376410-74-1P 376410-75-2P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 229477-44-5 244008-03-5, PN: WO9947540 SEQID: 3 unclaimed DNA 244008-06-8, PN: WO9947540 SEQID: 4 unclaimed DNA 244008-07-9, PN: WO9947540 SEQID: 5 unclaimed DNA 244008-08-0, PN: WO9947540 SEQID: 6 unclaimed DNA 244008-09-1, PN: WO9947540 SEQID: 7 unclaimed DNA 244008-12-6, 8: PN: WO0183510 SEQID: 8 unclaimed DNA 244008-13-7, PN: WO9947540 SEQID: 9 unclaimed DNA 244008-14-8, PN: WO9947540 SEQID: 10 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377754-45-5
RL: PRP (Properties)
(unclaimed sequence; human nucleic acids and their encoded proteins and antibodies)

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:435111 HCAPLUS
DN 135:29911
TI DNA encoding twenty-one human extracellular matrix and cell adhesion molecules
IN Yue, Henry; Tang, Y. Tom; Lal, Preeti; Burford, Neil; Azimzai, Yalda; Patterson, Chandra; Baughn, Mariah R.; Lu, Dyung Aina M.; Shah, Purvi; Au-young, Janice
PA Incyte Genomics, Inc., USA; et al.
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001042285	A2	20010614	WO 2000-US32990	20001205
WO 2001042285	A3	20020307		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1244695 A2 20021002 EP 2000-989218 20001205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2003044913 A1 20030306 US 2002-149819 20020610

PRAI US 1999-172852P P 19991210
US 1999-172354P P 19991216
WO 2000-US32990 W 20001205

AB The invention provides human extracellular matrix and cell adhesion mols. (XMAD) and polynucleotides which identify and encode XMAD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders assocd. with expression of XMAD.

IT Bladder
Brain
Drugs
Kidney, neoplasm
Lung, neoplasm
Mammary gland
Nucleic acid hybridization
PCR (polymerase chain reaction)
Protein sequences
Stomach, neoplasm
Synovial membrane
Testis, neoplasm
cDNA library
cDNA sequences
(DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Cell adhesion molecules
RL: ANT (Analyte); ANST (Analytical study)
(DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Antibodies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Proteins, specific or class
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(XMAD (extracellular matrix and cell adhesion mol.); DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Molecular cloning
(XMAD; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Penis
(acuminate wart; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Uterus
(cervix; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Artery
(coronary; DNA encoding twenty-one human extracellular matrix and cell

adhesion mols.)
IT Uterus
(endometrium; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Bronchi
(epithelium; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Animal tissue
(expression patterns in; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Proteins, specific or class
RL: ANT (Analyte); ANST (Analytical study)
(extracellular matrix-assocd.; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Immunoglobulins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(fragments; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Animal cell line
(hNT2; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Chromosome
(human; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Prostate gland
(neoplasm; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Intestine
(small; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT Salivary gland
(submandibular; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT 149408-35-5, Mucin MG 2 (human clone MG2-6-1 gene MUC7 precursor reduced) 252049-91-5 280786-68-7, Protein **ss3939** (human) 319020-53-6, Protein (human clone HP03377) 327142-80-3 343895-34-1 343895-35-2 343895-36-3 343895-37-4 343895-38-5 343895-39-6 343895-40-9 343895-41-0 343895-42-1 343895-43-2 343895-44-3 343895-45-4 343895-46-5 343895-47-6 343895-48-7 343895-49-8
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)
IT 343895-33-0 343895-50-1 343895-51-2 343895-52-3 343895-53-4 343895-54-5 343895-55-6 343895-56-7 343895-57-8 343895-58-9 343895-59-0 343895-60-3 343895-61-4 343895-62-5 343895-63-6 343895-64-7 343895-65-8 343895-66-9 343895-67-0 343895-68-1 343895-69-2
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(nucleotide sequence; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
AN 2000:457208 HCAPLUS
DN 133:85160
TI Protein and cDNA sequences of human protein **ss3939**, which has

homology to C-type lectins
IN Anderson, Dirk A.
PA Immunex Corporation, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039296	A1	20000706	WO 1999-US30523	19991222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002058310	A1	20020516	US 2001-887855	20010622
PRAI	US 1998-113820P	P	19981223		
	WO 1999-US30523	A1	19991222		

AB The invention provides protein and cDNA sequences of a novel protein, designated **ss3939**, which has an extracellular domain that has homol. to C-type lectin domains. The invention also provides chimeric proteins created by fusing **ss3939**, or fragments thereof, with an Fc protein. The invention further provides processes for prodn. of recombinant forms of **ss3939**, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(Fc/**ss3939**; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Immunoglobulins
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(fragments, Fc/**ss3939**; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Animal cell
Bacteria (Eubacteria)
Plant cell
Yeast
(host; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Chromosome
(human 11, mapping of **ss3939** gene to 11q22; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Animal cell
(mammalian, host; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Antibodies
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(monoclonal; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Genetic mapping
(of **ss3939** gene to h11q22; protein and cDNA sequences of

human protein **ss3939**, which has homol. to C-type lectins)
IT Proteins, specific or class
RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(oligomeric, **ss3939**; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Genetic engineering
Protein sequences
cDNA sequences
(protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Antibodies
Primers (nucleic acid)
Probes (nucleic acid)
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Mouse
(**ss3939** homolog from; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT Proteins, specific or class
RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(**ss3939**; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT 280786-68-7DP, Protein **ss3939** (human), subfragments are claimed
280786-69-8DP, 22-227-Protein **ss3939** (human), subfragments are claimed 280786-71-2P, 249-374-Protein **ss3939** (human)
RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(amino acid sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT 280786-67-6
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(nucleotide sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT 280788-08-1, 3: PN: WO0039296 SEQID: 3 unclaimed DNA 280788-09-2, 4: PN: WO0039296 SEQID: 4 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT 157214-04-5
RL: PRP (Properties)
(unclaimed protein sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
IT 98849-88-8 203244-38-6
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:491063 HCAPLUS
DN 139:57897
TI Novel pharmaceutical composition of interferon gamma or pirfenidone combined with molecular diagnostics for the improved treatment of interstitial lung diseases
IN Bevec, Dorian; Ziesche, Rolf
PA Mondobiotech SA, Switz.
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003051388	A2	20030626	WO 2002-CH691	20021212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2001-130011 A 20011218
AB The present invention relates to a novel pharmaceutical compn. of compds. having the biol. activity of interferon gamma (IFN-.gamma.) or pirfenidone in combination with a diagnostic array of candidate polynucleotides for the improved treatment of all forms of interstitial lung diseases, in particular of idiopathic pulmonary fibrosis (IPF). This invention describes the combination of mol. diagnosis and clin. therapy as a novel medication principle for redn. of mortality and improvement of disease management in interstitial lung diseases.
IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(14-3-3.sigma.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT Keratins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(15, BC002641; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT Keratins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(15; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT Keratins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(17, Z19574; pharmaceutical compn. of interferon gamma or pirfenidone

combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Keratins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(17; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Fibrillins
Thrombospondins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Thrombospondins
Uncoupling protein
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Keratins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(4, X07695; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Keratins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(5, M21389; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(5, U84722; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT G protein-coupled receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(51, AF056085; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Calcium-binding proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(A2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Annexins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(A8; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ADAN28, disintegrin and metalloproteinase domain 28, transcript variant 3: AF137335; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Hemoglobins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(AF349571, BC005931, NM_000519; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(AL133067; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Apo-2 ligand tumor necrosis factor (ligand) superfamily,member 10, U37518; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(B7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BCG induced integral membrane protein BIGMo-103; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BG538564, DKFZp564A132, AL049963; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BLu protein: U70824; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BLu protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Apolipoproteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(C-I; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CD209 antigen-like: AB015629; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CD24 signal transducer; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT CD antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CD52; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CGI-83 protein: BC000878; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CGI-92 protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CLONE=IMAGE:1032795=Hs.83623 nuclear receptor subfamily1; pharmaceutical compn. of interferon gamma or pirfenidone combined with

mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CLONE=IMAGE:1982571 ATPase, H+ transporting; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Disease, animal
(Churg-Strauss syndrome; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DDR1 (discoidin domain receptor 1), isoform b; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DEADH (Asp-Glu-Ala-AspHis) box **polypeptide**; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZP586G011; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp434A119; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp434A119; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp564A132; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp564D066, AL050025; pharmaceutical compn. of interferon gamma or

pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp564D193; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp586E1124; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp586M1120; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DKFZp761N09121: BF435376; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Duffy blood group: U01839; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E-, type 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E74-like factor 3 (ets domain transcription factor,epithelial-specific) : U73844; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E74-like factor 3 (ets domain transcription factor; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Escherichia coli

(EPEC, ETEC, EIEC, EHEC; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ10430: NM 018092.1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ10921; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ10970; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ11767; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ12983; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ13110; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ13310; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ13945 fis, clone Y79AA1000969; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ14054; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ21616; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ23049; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FLJ23571; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FYN oncogene: N20923; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT GABA receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(GABAA, .alpha.5; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT **DNA** microarray technology
(GENECHIP; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(GTP-binding, similar to RAYRAB1C:BC000566; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Kidney, disease
(Goodpasture's syndrome; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Apolipoproteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(H; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA (human leukocyte-assocd. antigen), B51, DR beta 5,35 M11867; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA (human leukocyte-assocd. antigen), B51; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA (human leukocyte-assocd. antigen), DQ alpha 1,M33906; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA (human leukocyte-assocd. antigen), DR beta 1, M33600; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA (human leukocyte-assocd. antigen), HLA-B39; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HNF-3.alpha. (hepatocyte nuclear factor 3.alpha.); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Heat-shock proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HSP 104, 105kD, D86956; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HSPC156; pharmaceutical compn. of interferon gamma or pirfenidone

combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Fibronectins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(I; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Insulin-like growth factor-binding proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(IGFBP-2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Insulin-like growth factor-binding proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(IGFBP-6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ILD differentially exppressed; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ISGF-3: M97935; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Jagged2 (JAG2); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein re-tention receptor 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(KIAA0362 gene, MCF.2 cell line derived transforming se-15 quence-like: AB002360; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(KIAA0372; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(KIAA0433; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(KIAA1199; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(KIAA1598; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Ribosomal proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(L37A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(LIM domain protein: BC003096; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(LUNX protein; PLUNC (palate lung and nasal epitheliumclone); :AB024937; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT CD2 (antigen)
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(M16445; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Thrombomodulin
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)
(M16552; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Perforin
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(M28393; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Interleukin 7 receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(M29696; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MAD (mothers against decapentaplegic, Drosophila) homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MGC:2854; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class II, DQ beta 1, AW276186; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class II, .alpha.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Mucins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MUC4, sv7-MUC4 apomucin, tracheobronchial; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Mucins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(MUC4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Mucins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MUC5; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MUF1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NG22; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NTT5; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P311 protein: U36189; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PRO2834: AF119903; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PTH-responsive osteosarcoma B1 protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT G proteins (guanine nucleotide-binding proteins)
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RAB, member of RAS oncogene family-like 2A: AF095350; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RAS guanyl releasing protein 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Ras-related assocd. with diabetes: L24564; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Ras-related assocd. with diabetes; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Calcium-binding proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(S100; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Calcium-binding proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(S100A4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Ribosomal proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(S4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SAM domain; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SB classII, alpha-chain, AI128225; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SH3-contg. protein SH3GLB2; pharmaceutical compn. of interferon gamma

or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SMC (mouse) homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(STAT1 (signal transducer and activator of transcription 1); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(T-cell specific, HMG-box; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transforming growth factor receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TGF-.beta. receptor, type I; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Granulomatous disease
(Wegener's granulomatosis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Wilms tumor 1, (WT1), variant D; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transport proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(X transporter protein 3: NM_020208.1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(adaptor-related protein complex 1, mu 2 subuni; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(adipose differentiation-related protein, BC005127; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Filamin
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(alpha (actin-binding protein-280); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Glycoproteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(alpha-2-HS-glycoprotein, BG538564; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(anterior gradient 2 (Xenepus laevis) homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(aquaporine 3 (water channel), AQP3 gene, AB001325; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ataxia-telangiectasia group D-assocd. protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Dyneins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(axonemal, intermediate **polypeptide**: AF091619; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(bone marrow stromal cell antigen 1, D21878; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(brain specific protein (LOC51673): AF132972; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(calcitonin receptor-like: L76380; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Calcium-binding proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(calgranulin A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(carboxypeptidase B-like protein: AB011969; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Drug delivery systems
(carriers; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cerebellar degeneration-related protein (34kD), M16965; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(chitinase 3-like 1 (cartilage glycoprotein-39): M80927; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(chitinase 3-like 2: U58515; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(chloride intracellular channel 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(chondroitin sulfate proteoglycan 2 (versican); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(**chromosome 11** open reading frame 16; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(claudin-3; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(claudins, 15; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(clone MGC:12387: M16942; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(clone=IMAGE-2406340: AI830563; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Complement
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(component 6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cysteine-rich, 1, BC002738; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(deleted in lung and esophageal cancer 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Mycobacterium
(diagnosis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Bacteria (Eubacteria)
Fungi
Mycoplasma
Virus
Yeast
(diagnostics; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(disintegrin and metalloproteinase domain 28 (ADAM28), isoform 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(disintegrin and metalloproteinase domain 9 (meltringamma) (ADAM9): U41766; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(disks, large (Drosophila) homolog 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(diubiquitin; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Initiation factors (protein formation)
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(eIF-1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(endothelial PAS domain protein 1, U51626; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cytokines
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(eosinophil chemotactic, TSA1902; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ephrin, EPHA3, AF213459; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ephrin; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(expressed in osteoblast: AB000115; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(eyes absent (Drosophila) homolog 2: U71207; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fatty acid binding protein 4, adipocyte, BC003672; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fatty acid binding protein 6, U19869; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fenestrated-endothelial linked structure protein (FELS),PVl protein (PLVAP): AF326591; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fibronectin leucine rich transmembrane protein 2, AB007865.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Lung, disease
(fibrosis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial

lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fibulin, 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT **cDNA** library
(for ILD differentially exppressed genes; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Genomic library
(for infection agents genes; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(forkhead box J1 (FOXJ1); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(forkhead box J1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Agglutinins and **Lectins**
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(galectin-7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(guanylate binding protein 1, interferon-inducible, 67kD:BC002666; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(haptoglobin-related protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(hematopoietic PBX-interacting protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(hepatic leukemia factor: M95585; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(hydroxyacid oxidase homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Lung, disease
(hypersensitivity pneumonitis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Drug delivery systems
(inhalants; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT CD antigens
Integrins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(integrin .alpha.7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interferon, alpha-inducible protein (clone IFI-6-16); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interferon, alpha-inducible protein 27: NM_005532; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interferon, gamma-inducible protein 30, AF097362; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interferon-stimulated protein, 15 kDa (ISG15): M13755; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interleukin 1 receptor-like 1 (IL1RL1): NM 003856.1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interleukin 1 receptor-like 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Interleukin receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interleukin 13; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Dyneins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(intermediate chain 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Lung, disease
(interstitial; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(klotho; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(latent transforming growth factor beta binding protein 4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT G protein-coupled receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(latrophilin; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(leiomodin 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Polynucleotides
RL: ARG (Analytical reagent use); DEV (Device component use); DGN

(Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(library of, pharmaceutical compn. comprising; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(lipocalin, 2 (oncogene 24p3); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(lung type-I cell membrane-assocd. glycoprotein, AU154455; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(lysosomal-assocd. membrane protein 2: J04183; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(macrophage receptor with collagenous structure, MARCO, AF035819; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(matrilin 3; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(matrix assocd., actin dependent regulator of chromatin, subfamily f, member 1, AF231056; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Glycoproteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(membrane, LIG-1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Polyamide fibers, uses
RL: DEV (Device component use); USES (Uses)
(membrane, diagnostic array on; pharmaceutical compn. of interferon

gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(membrane, golgi, GP73; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(mesoderm specific transcript (mouse) homolog: BC002413; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(microtubule-assocd. protein, RPEB family; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Diagnosis
(mol., combination with therapy; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monokine induced by gamma interferon; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(myosin regulatory light chain 2, smooth muscle isoform; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(nasopharyngeal epithelium specific protein 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(natural killer cell group 7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(nectin-like protein 2 (NECL2): AF132811; pharmaceutical compn. of

interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteoglycans, biological studies
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(neuroglycan C; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(neuroligin; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(neuronal specific, DAT1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(nidogen (enactin): M30269; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(non-specific cross reacting antigen; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(nuclear receptor subfamily 4, group A, member 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(nuclear receptor subfamily 4, group A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Membranes, nonbiological
(nylon, or nitrocellulose, diagnostic array on; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ound in inflammatory zone 3 (FIZZ3), AF323081; pharmaceutical compn.

of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peroxisome biogenesis factor 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Glucocorticoids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. comprising; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Acinetobacter baumannii
Acinetobacter calcoaceticus
Aeromonas
Bartonella bacilliformis
Bartonella henselae
Borrelia
Brucella
Burkholderia cepacia
Calymmatobacterium granulomatis
Campylobacter fetus
Campylobacter jejuni
Cardiobacterium hominis
Chlamydia
Citrobacter
Eikenella corrodens
Enterobacter
Fungi
Fusobacterium
Gardnerella vaginalis
Hepadnaviridae
Human adenovirus
Human herpesvirus
Influenza virus
Klebsiella
Lab-on-a-chip
Leptospira interrogans
Moraxella catarrhalis
Morganella (bacterium)
Mycoplasma
Nucleic acid hybridization
Paramyxovirus
Porphyromonas
Prevotella
Prognosis
Proteus (bacterium)
Providencia
Pseudomonas aeruginosa
Retroviridae
Rheumatoid arthritis
Rickettsia prowazeki
Salmonella enterica
Serratia
Shigella
Staphylococcus aureus
Stenotrophomonas maltophilia
Streptococcus

Susceptibility (genetic)
Toxoplasma
Treponema pallidum
Vibrio cholerae
Yeast
Yersinia enterocolitica
(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Biglycans
CD14 (antigen)
CD36 (antigen)
Calretinin
Elastins
Ezrin
Ferritins
Insulin-like growth factor I receptors
Integrins
Interleukin 7 receptors
Leukosialin
Myelin basic protein
RANTES (chemokine)
Transferrin receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Antibodies
Oligonucleotides
Probes (**nucleic acid**)
RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(plectins, intermediate filament binding protein, 500kD; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(plexin, B1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(prosaposins; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(protein C, endothelial (EPCR), L35545; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(protocadherin, 12, AF231025; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(protocadherin, 17, AF029343; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(protocadherin, .alpha.12; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(pulmonary surfactant protein (SP5), J03553; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ranslocase of inner mitochondrial membrane 8 (yeast) ho-molog A: BC005236; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(regulator of G protein signaling-Z (RGSZ1): AF060877; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(retinol-binding protein 4, interstitial, AF119868; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(rocollagen C-endopeptidase enhancer 2, AF098269; pharmaceutical compn.

of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Connective tissue, disease
(scleroderma; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(semaphorin, sem2: AB029496; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(serine threonine kinase 11 (STK11); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(similar to swine acylneuraminatelyase; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Drug delivery systems
(single dose; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Glass, uses
Glass beads
RL: DEV (Device component use); USES (Uses)
(slide, diagnostic array on; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(small inducible cytokine subfamily A (Cys-Cys), member 18, AB000221; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(small inducible cytokine subfamily A (Cys-Cys); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Chemokines
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(small inducible cytokine subfamily B (Cys-X-Cys), member 11: AF002985; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(small inducible cytokine subfamily C, member 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transport proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(solute carrier family 14 (urea transporter), member 1(Kidd blood group): U35735; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transport proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(solute carrier family 14 (urea transporter), member 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transport proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(solute carrier family 6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(sorting nexin 10, (SNX10), AF121860; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(sperm assocd. antigen 6: AF079363; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Antigens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(sperm assocd. antigen 6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(surfactant, pulmonary-assocd. protein A2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)
(surfactant, pulmonary-assocd. protein C, BC005913; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Lupus erythematosus
(systemic; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(tetraspan, transmembrane 4 superfamily member; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(tetraspanin, TM4-C; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(transmembrane 4 superfamily member 1, M90657; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(tumor necrosis factor .alpha.-induced protein 6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Fibroblast growth factor receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type 2, M80634; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Collagens, biological studies
Scavenger receptors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type I; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Collagens, biological studies
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type IV, .alpha.3; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Collagens, biological studies
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type V, .alpha.2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Collagens, biological studies
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type VII, 1, L02870; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Collagens, biological studies
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type XIV, CLONE=IMAGE:3579023; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Gene expression profiles, animal
(use in diagnostics; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(vascular cell adhesion mol. 1: M60335; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(wingless-type MMTV integration site family, member 5A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(zinc finger-contg., 331: AF272148; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(zinc finger-contg., Cip1-interacting; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Integrins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.alpha.1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Integrins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.alpha.4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transforming growth factors
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.beta.1-; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Tubulins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.beta.2-, BC002783; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Microglobulins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.beta.2-; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Integrins
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.beta.4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Interferons
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.gamma., X87308; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Interferons
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma., pegylated, (PRG-IFN-.gamma.); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Fibrinogens
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.gamma.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9048-63-9, Epoxide hydrolase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2, cytoplasmic: AF233334; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 109136-49-4, Ubiquitin specific protease
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(9; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9031-94-1, Aminopeptidase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(AF191545; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9031-98-5, Carboxypeptidase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(B1, (tissue), M81057; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 172521-74-3, Relaxin 1
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BC005956; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9026-43-1, Serine/threonine kinase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Fas-interacting, 3; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 321976-25-4, Sialyltransferase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(U14550; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9035-51-2, Cytochrome P 450, biological studies
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(XXVIIA, M62401; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9025-82-5, Phosphodiesterase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cAMP-specific, NM_000923; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 7440-21-3, Silicon, uses
RL: DEV (Device component use); USES (Uses)
(chip; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial

lung diseases (ILD))
IT 139691-92-2, Serine proteinase inhibitor
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(clade B (ovalbumin), member 5 (SERPINB5): U04313; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 9001-62-1, Lipase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(endothelial: AF118767; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 9023-09-0, Sulfotransferase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(family, cytosolic, 1C, member 1:AF186254; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 9028-86-8, Aldehyde dehydrogenase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(family, member A1: BC004370; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 9033-07-2, UDP-Glycosyltransferase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(family, **polypeptide** A1:M57899; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 117849-44-2, Gastrotropin
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fatty acid binding protein 6, ileal; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 9001-84-7, Phospholipase A2
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(group IIA; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 9029-17-8, Proline oxidase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
IT 9014-51-1, Indoleamine 2,3-dioxygenase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interferon-gamma-inducible; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9013-18-7
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(long-chain 4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 372092-80-3, Protein kinase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(male germ cell-assocd.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9004-70-0, Nitrocellulose
RL: DEV (Device component use); USES (Uses)
(membrane, diagnostic array on; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9001-59-6, Pyruvate kinase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(muscle; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9001-06-3, Chitotriosidase) 9001-61-0, Leucine aminopeptidase 9014-42-0, Proteoglycan 4 9025-62-1, Steroid sulfatase 9027-95-6, ATP citrate lyase 9047-22-7, Cathepsin B 9082-73-9, Steroid dehydrogenase 37270-94-3, Platelet factor 4 50812-37-8, Glutathione S-transferase 60202-07-5, Cholesterol 25-hydroxylase 71965-46-3, Cathepsin S 80295-33-6, Complement C1q 80295-41-6, Complement C3 82249-77-2, Arachidonate 15-lipoxygenase 87397-91-9, Thymosin .beta.10 109489-77-2, Tetranectin 120038-28-0, Carboxypeptidase M 140610-48-6, Matrix metalloproteinase 10 141256-52-2, Matrix metalloproteinase 7 143180-74-9, Granzyme B 149371-18-6, Legumain 151185-16-9, Fibroblast growth factor 9 151662-20-3, Myotonic dystrophy kinase 160477-63-4, Tissue factor pathway inhibitor 2 171715-12-1, Cathepsin Z 189460-40-0, Connective tissue growth factor 194739-73-6, MAP kinase kinase 6 196414-33-2, Disintegrin 198154-07-3, Cystatin F 227018-38-4, Neuropilin 2 334677-51-9, Cytochrome P450-IIB 377734-62-8, Granulysin
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 53179-13-8, Pirfenidone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 9001-77-8, Acid phosphatase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)
(phosphatidic, type 2C: BC002806; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT 97501-93-4, Tryptase
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.beta.III, mast cell; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

L12 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:645997 HCAPLUS
DN 137:228345
TI Molecular cloning and characterization of a novel mouse macrophage C-type **lectin**, mMGL2, which has a distinct carbohydrate specificity from mMGL1
AU Tsuiji, Makoto; Fujimori, Mayuko; Ohashi, Yoshimi; Higashi, Nobuaki; Onami, Thandi M.; Hedrick, Stephen M.; Irimura, Tatsuro
CS Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, 113-0033, Japan
SO Journal of Biological Chemistry (2002), 277(32), 28892-28901
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB A novel mouse macrophage galactose-type C-type lectin 2 (mMGL2) was identified by BLAST anal. of expressed sequence tags. The sequence of mMGL2 is highly homologous to the mMGL, which should now be called mMGL1. The open reading frame of mMGL2 contains a sequence corresponding to a type II transmembrane protein with 332 amino acids having a single extracellular C-type lectin domain. The 3'-untranslated region included long terminal repeats of mouse early transposon. The Mgl2 gene was cloned from a 129/SvJ mouse genomic library and sequenced. The gene spans 7,136 base pairs and consists of 10 exons, which is similar to the genomic organization of mMGL1. The reverse transcriptase-PCR anal. indicates that mMGL2 is expressed in cell lines and normal mouse tissues in a macrophage-restricted manner, also very similar to that of mMGL1. The mMGL2 mRNA was also detected in mMGL1-pos. cells, which were sorted from thioglycollate-induced peritoneal cells with a mMGL1-specific monoclonal antibody, LOM-8.7. The sol. recombinant proteins of mMGL2 exhibited carbohydrate specificity for .alpha.- and .beta.-GalNAc-conjugated sol. polyacrylamides, whereas mMGL1 preferentially bound Lewis X-conjugated sol. polyacrylamides in solid phase assays. These two lectins may function cooperatively as recognition and endocytic mols. on macrophages and related cells.

IT Agglutinins and **Lectins**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(C-type (calcium-dependent type), mMGL2; mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)

IT Protein motifs
(C-type **lectin** domain; mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)

IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(Mgl2; mol. cloning and characterization of a novel mouse macrophage

C-type **lectin** mMGL2)
IT Gene, animal
RL: PRP (Properties)
(Mgl2; mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)
IT **Protein sequences**
(amino acid sequence of mMGL2)
IT **DNA** sequences
(for C-type **lectin** of mouse macrophage)
IT Animal tissue
Genetic mapping
Macrophage
Mouse
(mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)
IT Promoter (genetic element)
RL: PRP (Properties)
(mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)
IT **Chromosome**
(mouse **11**; mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)
IT **cDNA** sequences
(nucleotide sequence for mMGL2)
IT 457115-93-4 457683-60-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)
IT 14131-60-3, .beta.-N-Acetyl-galactosamine 14215-68-0, .alpha.-N-Acetyl-galactosamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)
IT 432487-87-1, GenBank AY103461 432487-88-2, GenBank AY103462
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; mol. cloning and characterization of a novel mouse macrophage C-type **lectin** mMGL2)
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:636093 HCAPLUS
DN 135:209361
TI Novel human Breast cancer associated membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses
IN Boyd, Robert Simon; Stamps, Alasdair Craig; Terrett, Jonathan Alexander
PA Oxford Glycosciences (UK) Ltd., UK
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001062784	A2	20010830	WO 2001-GB748	20010221
WO 2001062784	A3	20020131		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	BR 2001008659	A	20021105	BR 2001-8659	20010221
	EP 1257285	A2	20021120	EP 2001-905965	20010221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003524017	T2	20030812	JP 2001-562565	20010221
	US 2003130214	A1	20030710	US 2001-791392	20010223
	US 2003099662	A1	20030529	US 2002-227616	20020823
PRAI	GB 2000-4576	A	20000225		
	GB 2000-31341	A	20001221		
	WO 2001-GB748	W	20010221		

AB The present invention provides novel human proteins (BCMP 11, 81 and 84) isolated from breast cancer cell line membrane prepns., compns. comprising the protein, including vaccines and antibodies which are immunospecific for the protein. The gene encoding BCMP 11 is mapped on human chromosome 7p21. BCMP 84 gene is mapped on human chromosome 1q21. The use of the protein in the diagnosis, screening, treatment and prophylaxis of breast cancer is also provided.

IT Genetic mapping
(BCMP **11** mapped on human **chromosome** 7p21; BCMP 84 gene mapped on human chromosome 1q21; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Agglutinins and **Lectins**
Carbohydrates, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(as capture agents for BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Diagnosis
(cancer; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Drugs
(comprising BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Antibodies
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(conjugates; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Mammary gland
(detecting BCMP expression from; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Polyacrylamide gel electrophoresis
(for detecting BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Test kits
(for diagnosis of cancer; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Antisense **DNA**
Ribozymes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for modulating BCMP expression or activities; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Chromosome
(human 1, q21, BCMP 84 gene mapped on; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Chromosome
(human 7, p21, BCMP 11 gene mapped on; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Diagnosis
(immunodiagnosis; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Antitumor agents
(mammary gland, metastasis; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Antitumor agents
(mammary gland; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Proteins, specific or class
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(membrane, BCMP 11; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Proteins, specific or class
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(membrane, BCMP 81; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Proteins, specific or class
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(membrane, BCMP 84; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Mammary gland
(metastasis, inhibitors; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
IT Diagnosis
(mol.; **protein** and **cDNA sequences** of

novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Antibodies
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Mammary gland
(neoplasm, inhibitors; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Mammary gland
(neoplasm; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Drug screening
Molecular cloning
(**protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Antibodies
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(**protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Immobilization, biochemical
(protein, of BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-assocd., BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Vaccines
(tumor; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Immunization
(vaccination, against breast cancer; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Antitumor agents
(vaccines; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT 21820-51-9, phosphotyrosine
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(as capture agents for BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT 357142-80-4 357142-91-7 357142-92-8 357466-26-3 357466-27-4
357466-28-5 357466-29-6 357466-30-9 357466-31-0 357676-37-0
357676-39-2 357676-40-5 357676-44-9, 7: PN: WO0162784 PAGE: 107

unclaimed **DNA** 357676-45-0, 8: PN: WO0162784 PAGE: 107
unclaimed **DNA** 357692-25-2 357692-26-3 357693-30-2
357693-31-3 357693-32-4 357693-33-5 357693-34-6 357693-35-7
357693-36-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT 204081-34-5, Growth factor XAG-1 (human precursor) 204081-38-9, Growth factor XAG-3 (human precursor) 222614-91-7 357464-92-7, Protein BCMP 84 (human)
RL: PRP (Properties)
(unclaimed **protein sequence**; novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT 216157-12-9 357609-73-5 357609-74-6 357609-89-3 357609-90-6
357627-10-2 357627-11-3 357656-18-9 357656-19-0 357656-20-3
357656-21-4 357656-22-5 357656-23-6 357656-24-7 357656-25-8
357656-26-9 357656-27-0 357656-28-1 357656-29-2 357656-30-5
357656-31-6 357656-32-7 357656-33-8 357656-35-0 357656-37-2
357656-38-3 357656-39-4 357656-41-8 357656-42-9 357656-43-0
357656-44-1 357656-45-2 357656-46-3 357656-47-4 357656-48-5
357656-49-6 357656-50-9 357656-51-0 357656-52-1 357656-53-2
357656-54-3 357656-55-4 357656-56-5 357656-57-6 357656-58-7
357656-59-8 357656-60-1 357656-61-2 357656-62-3 357656-63-4
357656-64-5 357656-65-6 357656-66-7 357656-67-8 357656-68-9
357656-69-0 357656-70-3 357656-71-4 357656-72-5 357656-73-6
357656-74-7 357656-75-8 357656-76-9 357656-77-0 357656-78-1
357656-79-2 357656-80-5 357656-81-6 357656-82-7 357656-83-8
357656-84-9 357656-85-0 357656-86-1 357656-87-2 357656-88-3
357656-89-4 357656-90-7 357656-91-8 357656-92-9 357656-93-0
357656-94-1 357656-95-2 357656-96-3 357656-97-4
RL: PRP (Properties)
(unclaimed sequence; novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

L12 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:448136 HCAPLUS
DN 136:162023
TI The human gene for mannan-binding **lectin**-associated serine protease-2 (MASP-2), the effector component of the **lectin** route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3
AU Stover, C.; Endo, Y.; Takahashi, M.; Lynch, N. J.; Constantinescu, C.; Vorup-Jensen, T.; Thiel, S.; Friedl, H.; Hankeln, T.; Hall, R.; Gregory, S.; Fujita, T.; Schwaeble, W.
CS Department of Microbiology and Immunology, University of Leicester, Leicester, LE1 9HN, UK
SO Genes and Immunity (2001), 2(3), 119-127
CODEN: GEIMA2; ISSN: 1466-4879
PB Nature Publishing Group
DT Journal
LA English
AB The proteases of the lectin pathway of complement activation, MASP-1 and MASP-2, are encoded by two sep. genes. The MASP1 gene is located on chromosome 3q27, the MASP2 gene on chromosome 1p36.23-31. The genes for the classical complement activation pathway proteases, C1r and C1s, are linked on chromosome 12p13. We have shown that the MASP2 gene encodes two gene products, the 76 kDa MASP-2 serine protease and a plasma protein of 19 kDa, termed MAp19 or sMAP. Both gene products are components of the

lectin pathway activation complex. We present the complete primary structure of the human MASP2 gene and the tight cluster that this locus forms with non-complement genes. A comparison of the MASP2 gene with the previously characterized C1s gene revealed identical positions of introns sepg. orthologous coding sequences, underlining the hypothesis that the C1s and MASP2 genes arose by exon shuffling from one ancestral gene.

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(CDT6 (cornea-derived transcript 6); of cornea-derived transcript 6 (CDT6) protein, gene located on chromosome 1p36.2-3 near the MASP-2 gene)

IT **DNA** sequences
(**DNA** sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(**DNA** sequence and initial promoter characterization of human gene MASP2, including transcription start site, and putative binding sites for transcription factors)

IT Genetic polymorphism
Human
(**DNA** sequence, genomic organization, genetic polymorphism, initial promoter characterization, and chromosomal organization of human gene MASP2, encodes MASP-2 serine protease, and sMAP (MAp19))

IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(MASP-2; **DNA** sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)

IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(PM-scl; **DNA** sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)

IT RNA splicing
(alternative; human gene MASP2 encodes sMAP (MAp19) protein due to alternative splicing and polyadenylation)

IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(autoantigens, PM-scl (polymyositis-scleroderma); of human polymyositis-scleroderma autoantigen (PM-scl), gene located on chromosome 1p36.2-3 near the MASP-2 gene)

IT Chromosome
(human 1, 1p36.23-31; **DNA** sequence, genomic organization, genetic polymorphism, initial promoter characterization, and chromosomal organization of human gene MASP2, encodes MASP-2 serine protease, and sMAP (MAp19))

IT Complement
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**lectin** pathway; chromosomal organization of human gene MASP2, encodes mannan-binding **lectin**-assocd. serine protease-2, and sMAP (MAp19), two components of **lectin** pathway activation complex)

IT Evolution

(mol.; **DNA** sequence and characterization of human mannan-binding **lectin**-assocd. serine protease-2 (MASP-2) gene, including hypothesis that C1s and MASP2 genes arose by exon shuffling from one ancestral gene)

IT **Protein sequences**
(of proteins encoded by genes on human chromosome 1p36.2-3, including MASP-2, sMAP (MAp19), PM-scl, FRAP kinase and CDT6)

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(sMAP (small MBL-assocd. protein), also known as MAp19; sequence and protein motifs of human mannan-binding **lectin**-assocd. serine protease-2, and sMAP (MAp19))

IT **Protein** motifs
(**sequence** and protein motifs of human mannan-binding **lectin**-assocd. serine protease-2, and sMAP (MAp19))

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tsp (transcription start point); **DNA** sequence and initial promoter characterization of human gene MASP2, including transcription start site, and putative binding sites for transcription factors)

IT 395688-05-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; of cornea-derived transcript 6 (CDT6) protein, gene located on chromosome 1p36.2-3 near the MASP-2 gene)

IT 395688-04-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; of human phosphatidylinositol kinase FRAP, gene located on chromosome 1p36.2-3 near the MASP-2 gene)

IT 395688-03-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; of human polymyositis-scleroderma autoantigen (PM-scl), gene located on chromosome 1p36.2-3 near the MASP-2 gene)

IT 395687-99-7 395688-00-3 395688-01-4 395688-02-5
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequence and protein motifs of human mannan-binding **lectin**-assocd. serine protease-2, and sMAP (MAp19))

IT 302876-75-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; **DNA** sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)

IT 233581-98-1, GenBank AL109811
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; **DNA** sequence of genes found on human **chromosome** 1p36.**11**-1p36.31)

IT 245103-40-6, GenBank AB033742 290791-85-4, GenBank AJ299718
304836-23-5, GenBank AJ297949
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; **DNA** sequence, genomic organization, genetic polymorphism, initial promoter characterization, and chromosomal organization of human gene MASP2, encodes MASP-2 serine

protease, and sMAP (MAp19))
IT 171715-28-9, Protein kinase FRAP
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(of human phosphatidylinositol kinase FRAP, gene located on chromosome 1p36.2-3 near the MASP-2 gene)
IT 214915-16-9, Mannan-binding **lectin**-associated serine protease-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(sequence and protein motifs of human mannan-binding **lectin**-assocd. serine protease-2, and sMAP (MAp19))
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:756719 HCAPLUS
DN 133:330541
TI Cloning and **cDNA** sequence encoding human galectin 11
IN Ni, Jian; Rosen, Craig A.; Gentz, Reiner L.; Lui, Fu-Tong
PA Human Genome Sciences, Inc., USA; Lajolla Institute for Allergy and Immunology
SO PCT Int. Appl., 314 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 36

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000063221	A2	20001026	WO 2000-US10714	20000421
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1192168	A1	20020403	EP 2000-923556	20000421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002541832	T2	20021210	JP 2000-612311	20000421
PRAI	US 1999-130390P	P	19990421		
	US 1999-169932P	P	19991210		
	WO 2000-US10714	W	20000421		

AB The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid mols. are provided encoding the human galectin 11 proteins, including isoform .alpha. and .beta. resulted from alternative RNA splicing. The human galectin 11 gene is located on chromosome 11, contains 5 exons, and the cDNA has an open reading frame encoding a protein of 133 amino acid residues. The galectin 11 protein shares homol. with rat galectin 5, chicken galectin 3, and human galectin 8. Transfection of Jurkat cells with a galectin 11 expression construct induces apoptosis of transfected T-cells. Also provided are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of galectin 11 activity. Also provided are diagnostic and therapeutic methods.
IT Animal cell line
(CHO, recombinant expression host; cloning and **cDNA** sequence

encoding human galectin 11)
IT Animal cell line
(COS, recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT Animal cell line
(SF9, recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT T cell (lymphocyte)
(apoptosis induction; cloning and **cDNA** sequence encoding human galectin 11)
IT Diagnosis
(cancer; cloning and **cDNA** sequence encoding human galectin 11)
IT Drug delivery systems
(carriers; cloning and **cDNA** sequence encoding human galectin 11)
IT Allergy inhibitors
Anti-inflammatory agents
Antiasthmatics
Antitumor agents
Molecular cloning
(cloning and **cDNA** sequence encoding human galectin 11)
IT Antibodies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cloning and **cDNA** sequence encoding human galectin 11)
IT Immunoassay
(detection by; cloning and **cDNA** sequence encoding human galectin 11)
IT Autoimmune disease
(diagnosis and treatment of; cloning and **cDNA** sequence encoding human galectin 11)
IT Cell differentiation
Cell proliferation
(diagnosis of disorders of; cloning and **cDNA** sequence encoding human galectin 11)
IT **cDNA** sequences
(for human galectin 11; cloning and **cDNA** sequence encoding human galectin 11)
IT Gene, animal
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(for human galectin 11; cloning and **cDNA** sequence encoding human galectin 11)
IT Agglutinins and **Lectins**
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(galectin-11; cloning and **cDNA** sequence encoding human galectin 11)
IT Genetic mapping
(gene mapping and organization on human **chromosome 11** ; cloning and **cDNA** sequence encoding human galectin 11)
IT **Chromosome**
(human **11**, gene mapping and organization on human **chromosome 11**; cloning and **cDNA** sequence encoding human galectin 11)
IT Apoptosis
(induced in T-cells; cloning and **cDNA** sequence encoding human galectin 11)

IT Animal cell
(mammalian, recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT Diagnosis
(mol.; cloning and **cDNA** sequence encoding human galectin 11)
IT **Protein sequences**
(of human galectin 11; cloning and **cDNA** sequence encoding human galectin 11)
IT Escherichia coli
(recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT 303071-83-2DP, Galectin 11 (human isoform .alpha.), subfragments claimed
303071-84-3DP, Galectin 11 (human isoform .beta.), subfragments claimed
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(amino acid sequence; cloning and **cDNA** sequence encoding human galectin 11)
IT 210478-30-1DP, Receptor (human clone HJACE54), subfragments claimed
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(cloning and **cDNA** sequence encoding human galectin 11)
IT 210478-29-8, **DNA** (human clone HJACE54 receptor **cDNA** plus flanks) 303071-85-4 303071-86-5
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(nucleotide sequence; cloning and **cDNA** sequence encoding human galectin 11)
IT 229477-44-5 244008-03-5, PN: WO9947540 SEQID: 3 unclaimed **DNA**
244008-06-8, PN: WO9947540 SEQID: 4 unclaimed **DNA** 244008-07-9, PN: WO9947540 SEQID: 5 unclaimed **DNA** 244008-08-0, PN: WO9947540 SEQID: 6 unclaimed **DNA** 244008-09-1, PN: WO9947540 SEQID: 7 unclaimed **DNA** 244008-12-6, 19: PN: WO9962934 PAGE: 65 unclaimed **DNA** 244008-13-7, PN: WO9947540 SEQID: 9 unclaimed **DNA** 244008-14-8, PN: WO9947540 SEQID: 10 unclaimed **DNA**
254855-13-5, 5: PN: WO0001728 SEQID: 7 unclaimed **DNA**
254855-14-6, 6: PN: WO0001728 SEQID: 8 unclaimed **DNA**
254855-16-8, 8: PN: WO0001728 SEQID: 10 unclaimed **DNA**
254855-17-9, 9: PN: WO0001728 SEQID: 11 unclaimed **DNA**
303072-63-1, 4: PN: WO0063221 SEQID: 6 unclaimed **DNA**
303072-64-2, 7: PN: WO0063221 SEQID: 9 unclaimed **DNA**
303072-66-4
RL: PRP (Properties)
(unclaimed nucleotide sequence; cloning and **cDNA** sequence encoding human galectin 11)
IT 165945-20-0 254855-10-2 303113-31-7
RL: PRP (Properties)
(unclaimed **protein sequence**; cloning and **cDNA** sequence encoding human galectin 11)
IT 210478-30-1, Receptor (human clone HJACE54) 303044-52-2 303072-67-5
303113-07-7
RL: PRP (Properties)
(unclaimed sequence; cloning and **cDNA** sequence encoding human galectin 11)

L12 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:34903 HCAPLUS
DN 132:89793

TI Cloning and **cDNA** sequence encoding human galectin 11
IN Rosen, Craig A.; Ni, Jian; Gentz, Reiner L.
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 36

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000001728	A1	20000113	WO 1999-US15169	19990702
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2336406	AA	20000113	CA 1999-2336406	19990702
	AU 9949695	A1	20000124	AU 1999-49695	19990702
	EP 1095060	A1	20010502	EP 1999-933694	19990702
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003512291	T2	20030402	JP 2000-558129	19990702
PRAI	US 1998-109864	A	19980706		
	WO 1999-US15169	W	19990702		

AB The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid mols. are provided encoding the human galectin 11 proteins. The human galectin 11 gene is located on chromosome 11, contains 5 exons, and the cDNA has an open reading frame encoding a protein of 133 amino acid residues. The galectin 11 protein shares homol. with rat galectin 5, chicken galectin 3, and human galectin 8. Transfection of Jurkat cells with a galectin 11 expression construct induces apoptosis of transfected T-cells. Also provided are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of galectin 11 activity. Also provided are diagnostic and therapeutic methods.

IT Animal cell line
(CHO, recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT Animal cell line
(COS, recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT Animal cell line
(SF9, recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT T cell (lymphocyte)
(apoptosis induction; cloning and **cDNA** sequence encoding human galectin 11)
IT Diagnosis
(cancer; cloning and **cDNA** sequence encoding human galectin 11)
IT Allergy inhibitors
Anti-inflammatory agents
Antiasthmatics
Antitumor agents
Drugs

Molecular cloning
(cloning and **cDNA** sequence encoding human galectin 11)
IT Antibodies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cloning and **cDNA** sequence encoding human galectin 11)
IT Immunoassay
(detection by; cloning and **cDNA** sequence encoding human galectin 11)
IT Autoimmune disease
(diagnosis and treatment of; cloning and **cDNA** sequence encoding human galectin 11)
IT Cell differentiation
Cell proliferation
(diagnosis of disorders of; cloning and **cDNA** sequence encoding human galectin 11)
IT Neoplasm
(diagnosis; cloning and **cDNA** sequence encoding human galectin 11)
IT **cDNA** sequences
(for human galectin 11)
IT Agglutinins and **Lectins**
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(galectin-11; cloning and **cDNA** sequence encoding human galectin 11)
IT Genetic mapping
(gene mapping and organization on human **chromosome 11** ; cloning and **cDNA** sequence encoding human galectin 11)
IT Gene, animal
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(gene mapping and organization on human **chromosome 11** ; cloning and **cDNA** sequence encoding human galectin 11)
IT **Chromosome**
(human **11**, gene mapping and organization on human **chromosome 11**; cloning and **cDNA** sequence encoding human galectin 11)
IT Apoptosis
(induced in T-cells; cloning and **cDNA** sequence encoding human galectin 11)
IT Animal cell
(mammalian, recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT Diagnosis
(mol.; cloning and **cDNA** sequence encoding human galectin 11)
IT **Protein sequences**
(of human galectin 11)
IT Escherichia coli
(recombinant expression host; cloning and **cDNA** sequence encoding human galectin 11)
IT 210478-30-1DP, Receptor (human clone HJACE54), subfragments are claimed
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; cloning and **cDNA** sequence encoding human galectin 11)
IT 210478-29-8DP, subfragments are claimed

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; cloning and **cDNA** sequence encoding human galectin 11)

IT 254855-11-3, 3: PN: WO0001728 SEQID: 5 unclaimed **DNA**
254855-12-4, 4: PN: WO0001728 SEQID: 6 unclaimed **DNA**
254855-13-5, 5: PN: WO0001728 SEQID: 7 unclaimed **DNA**
254855-14-6, 6: PN: WO0001728 SEQID: 8 unclaimed **DNA**
254855-15-7, 7: PN: WO0001728 SEQID: 9 unclaimed **DNA**
254855-16-8, 8: PN: WO0001728 SEQID: 10 unclaimed **DNA**
254855-17-9, 9: PN: WO0001728 SEQID: 11 unclaimed **DNA**
RL: PRP (Properties)
(unclaimed nucleotide sequence; cloning and **cDNA** sequence encoding human galectin 11)

IT 165945-20-0 254855-10-2
RL: PRP (Properties)
(unclaimed **protein sequence**; cloning and **cDNA** sequence encoding human galectin 11)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:629148 HCAPLUS
DN 132:261213
TI Genomic structure and chromosomal location of the mouse macrophage C-type **lectin** gene
AU Tsuiji, Makoto; Fujimori, Mayuko; Seldin, Michael F.; Taketo, Makoto M.; Irimura, T.
CS Laboratory of Cancer Biology and Molecular Immunology, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
SO Immunogenetics (1999), 50(1-2), 67-70
CODEN: IMNGBK; ISSN: 0093-7711
PB Springer-Verlag
DT Journal
LA English
AB The mouse macrophage c-type lectin (MGL) is a Gal/GalNAc-specific C-type lectin. The Mgl gene was cloned and sequenced. It consists of 10 exons. The Mgl gene was linked to transformation-related protein 53 (Trp53) and located on mouse chromosome 11.

IT Agglutinins and **Lectins**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(C-type (calcium-dependent type), galactose/N-acetylgalactosamine-specific; genomic structure and chromosomal location of mouse macrophage C-type **lectin** gene)

IT Molecular recognition
(carbohydrate; genomic structure and chromosomal location of mouse macrophage C-type **lectin** gene)

IT Genetic element
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(exon-intron junction; genomic structure and chromosomal location of mouse macrophage C-type **lectin** gene)

IT **DNA** sequences
Genetic mapping
Macrophage
Mouse
Protein sequences
RNA splicing
(genomic structure and chromosomal location of mouse macrophage C-type

lectin gene)
IT **Chromosome**
(mouse **11**; genomic structure and chromosomal location of mouse macrophage C-type **lectin** gene)
IT 263233-84-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; genomic structure and chromosomal location of mouse macrophage C-type **lectin** gene)
IT 225706-76-3, GenBank AF132744
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; genomic structure and chromosomal location of mouse macrophage C-type **lectin** gene)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:189359 HCAPLUS
DN 126:195991
TI Structural organization and expression of the gene for the mouse GM2 activator protein
AU Bertoni, C.; Appolloni, M.G.; Stirling, J.L.; Li, S-C.; Li, Y-T.; Orlacchio, A.; Beccari, T.
CS Dipartimento di Biologia Cellulare e Molecolare, Sezione di Biochimica e Biologia Molecolare, Universita di Perugia, Perugia, 06126, Italy
SO Mammalian Genome (1997), 8(2), 90-93
CODEN: MAMGEC; ISSN: 0938-8990
PB Springer
DT Journal
LA English
AB The GM2 activator protein is an essential component for the degrdn. of GM2 ganglioside by hexosaminidase A in vivo. Mutations in the human gene coding for the GM2 activator protein cause the AB variant of GM2-gangliosidosis, a condition that is clin. indistinguishable from Tay-Sachs disease. To understand better factors affecting the expression of the GM2 activator protein gene (Gm2a) in mouse tissues, we have detd. its exon-intron organization and analyzed its promoter region. Gm2a is about 14 kb, has four exons, and the 5' flanking region contains a CAAT box, Sp1 binding sites, AP-1, AP-2 sites, and a pair of IRE sites. A 1.2-kb fragment upstream from the initiation codon was shown to have promoter activity in NIH 3T3 cells. Similarities between the elements present in Gm2a and Hexa promoters might in part explain their similar expression patterns in mouse tissues. The different levels of GM2 activator protein mRNA in liver, kidney, brain, and testis are not owing to the use of different transcription start sites, because a single start site was found 50 bp upstream from the initiation codon in each these tissues. Northern blot anal. demonstrated variation in the GM2 activator protein mRNA expression during mouse development. Gm2a was mapped to Chromosome (Chr) 11, where it co-segregated with Csfgm.
IT Gene, animal
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(Gm2a; structural organization, mapping, and expression of the gene for the mouse GM2 activator protein)
IT Proteins, specific or class
RL: PRP (Properties)
(ganglioside GM2a hydrolysis-activating; structural organization, mapping, and expression of the gene for the mouse GM2 activator

protein)
IT **Chromosome**
(mouse **11**; mapping of mouse GM2 activator protein gene to **chromosome 11**)
IT **Protein sequences**
(of mouse GM2 activator protein)
IT Genetic mapping
(of mouse GM2 activator protein gene to **chromosome 11**)
IT **DNA** sequences
(of the gene for the mouse GM2 activator protein)
IT Mouse
(structural organization, mapping, and expression of the gene for the mouse GM2 activator protein)
IT 128004-04-6, **Lectin** (Aleuria aurantia clone .lambda.AAL-3 subunit precursor reduced)
RL: PRP (Properties)
(amino acid sequence; structural organization, mapping, and expression of the gene for the mouse GM2 activator protein)
IT 168580-79-8, Genbank U34356 168580-80-1, Genbank U34357 168580-81-2, Genbank U34358 168580-82-3, Genbank U34359
RL: PRP (Properties)
(nucleotide sequence; structural organization, mapping, and expression of the gene for the mouse GM2 activator protein)
IT 19600-01-2, Ganglioside GM2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(structural organization, mapping, and expression of the gene for the mouse GM2 activator protein)

L12 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:440637 HCAPLUS
DN 123:162447
TI Sequence and mapping of galectin-5, a .beta.-galactoside-binding **lectin**, found in rat erythrocytes
AU Gitt, Michael A.; Wiser, Mark F.; Leffler, Hakon; Herrmann, Joerg; Xia, Yurong; Massa, Stephen M.; Copper, Douglas N. W.; Lusis, Aldons J.; Barondes, Samuel H.
CS Center Neurobiology Psychiatry, Univ. California, San Francisco, CA, 94143-0984, USA
SO Journal of Biological Chemistry (1995), 270(10), 5032-8
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB A monomeric rat .beta.-galactoside-binding lectin previously purified from exts. of rat lung was localized to erythrocytes, and the cDNA encoding it was isolated from a rat reticulocyte cDNA library. The deduced amino acid sequence of the cDNA predicts a protein with a Mr of 16,199, with no evidence of a signal peptide. The deduced sequence is identical to the sequences of 7 proteolytic peptides derived from the purified lectin. Peptide anal. by mass spectrometry indicates that the N-terminal methionine is cleaved and that serine-2 is acetylated. The lectin shares all the strictly conserved amino acid residues of other members of the mammalian galectin family and is designated galectin-5 (GenBank accession no. L36862). Galectin-5 is a weak agglutinin of rat erythrocytes, despite its monomeric structure. The gene encoding galectin-5 (LGALS5) was mapped in mouse to chromosome 11, .apprx.50 centimorgans from the centromere and 1.8 centimorgans from the polymorphic marker D11Mit34n, a region syntenic with human chromosome 17q11.

IT Gene, animal
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(LGALS5; sequence and mapping of galectin-5, a .beta.-galactoside-binding **lectin**, found in rat erythrocytes)
IT Agglutinins and **Lectins**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(galectin-5; sequence and mapping of galectin-5, a .beta.-galactoside-binding **lectin**, found in rat erythrocytes)
IT **Protein sequences**
(of galectin-5 **lectin** from rat)
IT Genetic mapping
Mouse
Rat
(sequence and mapping of galectin-5, a .beta.-galactoside-binding **lectin**, found in rat erythrocytes)
IT Deoxyribonucleic acid sequences
(complementary, for galectin-5 **lectin** from rat)
IT **Chromosome**
(mouse **11**, sequence and mapping of galectin-5, a .beta.-galactoside-binding **lectin**, found in rat erythrocytes)
IT 164782-89-2, Galectin 5 (rat clone Le1h/Le2b) 165945-20-0
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; sequence and mapping of galectin-5, a .beta.-galactoside-binding **lectin**, found in rat erythrocytes)
IT 164956-62-1
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(nucleotide sequence; sequence and mapping of galectin-5, a .beta.-galactoside-binding **lectin**, found in rat erythrocytes)

L12 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:140975 HCAPLUS
DN 118:140975
TI Rat gene mapping using PCR-analyzed microsatellites
AU Serikawa, Tadao; Kuramoto, Takashi; Hilbert, Pascale; Mori, Masayuki; Yamada, Junzo; Dubay, Christopher J.; Lindpainter, Klaus; Ganten, Detlev; Guenet, Jean Louis; et al.
CS Fac. Med., Kyoto Univ., Kyoto, 606, Japan
SO Genetics (1992), 131(3), 701-21
CODEN: GENTAE; ISSN: 0016-6731
DT Journal
LA English
AB One hundred and seventy-four rat loci which contain short tandem repeat sequences were extd. from the GenBank or EMBL data bases and used to define primers for amplification by the polymerase chain reaction (PCR) of the microsatellite regions, creating PCR-formatted sequence-tagged microsatellite sites (STMSs). One hundred and thirty-four STMSs for 118 loci, including 6 randomly cloned STMSs, were characterized: (1) PCR-analyzed loci were assigned to specific chromosomes using a panel of rat .times. mouse somatic cell hybrid clones. (2) Length variation of the STMSs among 8 inbred rat strains could be visualized at 85 of 107 loci examd. (79.4%). (3) A genetic map, integrating biochem., coat color, mutant, and restriction fragment length polymorphism loci, was constructed based on the segregation of 125 polymorphic markers in 7 rat backcrosses and in two F2 crosses. Twenty-four linkage groups were identified, all of which were assigned to a defined chromosome. As a reflection of the bias for coding sequences in the public data bases, the STMSs described herein

are often assocd. with genes. Hence, the genetic map reported coincides with a gene map. The corresponding map locations of the homologous mouse and human genes are also listed for comparative mapping purposes.

IT Proteins, specific or class
RL: BIOL (Biological study)
(9Ka, gene for, mapping on rat chromosome of)

IT Rat
(gene and marker loci of, mapping of, PCR-analyzed microsatellite **DNA** in)

IT Hemoglobins
RL: BIOL (Biological study)
(gene for .beta.-chain of, linkage mapping of rat)

IT Albumins, biological studies
Haptoglobins
Immunoglobulins
Prealbumins
RL: BIOL (Biological study)
(gene for, mapping on rat chromosome of)

IT Myosins
RL: PRP (Properties)
(genes for light and heavy chains of, mapping on rat chromosome of)

IT Fibrinogens
RL: BIOL (Biological study)
(genes for .alpha. and .gamma. chains of, mapping on rat chromosome of)

IT Proteins, specific or class
RL: BIOL (Biological study)
(leukosianin-related, gene for, mapping on rat chromosome of)

IT Polymerase chain reaction
(microsatellite **DNA** analyzed by, for rat gene mapping)

IT Proteins, specific or class
RL: BIOL (Biological study)
(nerve growth factor-induced, mapping on rat chromosome of)

IT Receptors
RL: BIOL (Biological study)
(neuromedin K, gene for, linkage mapping of rat)

IT Genetic mapping
(of rat genes and arbitrary marker loci, PCR-analyzed microsatellite **DNA** in)

IT **Chromosome**
(rat **11**, gene mapping on, PCR-analyzed microsatellite **DNA** in)

IT Chromosome
(rat 12, gene mapping on, PCR-analyzed microsatellite **DNA** in)

IT Antigens
RL: BIOL (Biological study)
(thymus cell I, gene for, mapping on rat chromosome of)

IT Proteins, specific or class
RL: BIOL (Biological study)
(trypsin inhibitor-like, gene for, mapping on rat chromosome of)

IT Proteins, specific or class
RL: BIOL (Biological study)
(zitter, gene for, linkage mapping of rat)

IT Gene, animal
RL: BIOL (Biological study)
(BSIS, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)

IT Gene, animal
RL: BIOL (Biological study)
(DBPCEP, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)

IT Gene, animal
RL: BIOL (Biological study)
(FGA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(FABP1, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(FST, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(GJA1,, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(GLUTB, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(GCK, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(KCPVD, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(LALBA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(LSN, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(LSNR, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TKG, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TTR, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TILP, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TON, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TPM, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)

IT Gene, animal
RL: BIOL (Biological study)
(TRAG, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ZI, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(MBPA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(MYL2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(MYLC1V, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(MYCS, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(MYHSE, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(IGFBBP, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(IGF1, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(IGHE, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(IVD, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(INHA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(INS1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ADRB2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ADRA1B, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)

IT Gene, animal
RL: BIOL (Biological study)
(AGT, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(A2UG, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(AMPP, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ACRM, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(AEP, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CBPI, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CYPBE, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CYPE, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CALM3, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CEAR, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CPB, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CSNA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CSPMO2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ELAI, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ES6, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)

IT Gene, animal
RL: BIOL (Biological study)
(HAO1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(HEOXG, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(HHITTS, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(NGF1, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(NGFR, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(NKR, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(OLF, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PBPC2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PFKFB, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PFLG, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PG1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PKL, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PKATA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PKCS, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PLANH, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)

IT Gene, animal
RL: BIOL (Biological study)
(PTP, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(P9KA,mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PCK, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PERF, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PRLR, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(RBP2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(SVS2P, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(SCN2A, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(SECR, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(SHDL, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(SPAT, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(SPR, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Proteins, specific or class
RL: BIOL (Biological study)
(2, RBP2 (retinol-binding protein, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(ABP (androgen-binding protein), gene for, mapping on rat chromosome of)
IT Antigens
RL: BIOL (Biological study)
(CEA (carcinoembryonic antigen)-related, gene for, mapping on rat chromosome of)

IT Proteins, specific or class
RL: BIOL (Biological study)
(**DNA**-binding, C/ep, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(F1, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(FABP (fatty acid-binding protein), gene for, mapping on rat chromosome of)
IT Globulins, biological studies
RL: BIOL (Biological study)
(Gc, gene for, linkage mapping of rat)
IT G proteins (guanine nucleotide-binding proteins)
RL: BIOL (Biological study)
(Golf (olfactory nerve), gene for, mapping on rat chromosome of)
IT Histones
RL: BIOL (Biological study)
(H1t, gene for, mapping on rat chromosome of)
IT Histones
RL: BIOL (Biological study)
(H4t, gene for, mapping on rat chromosome of)
IT Genetic element
RL: BIOL (Biological study)
(ID element, brain-specific, mapping on rat chromosome of)
IT Glycoproteins, specific or class
RL: BIOL (Biological study)
(IGF-BP-3 (insulin-like growth factor-binding protein 3), gene for, mapping on rat chromosome of)
IT Calmodulins
RL: BIOL (Biological study)
(III, gene for, mapping on rat chromosome of)
IT Antigens
RL: BIOL (Biological study)
(L-CA (leukocyte common antigen), gene for, mapping on rat chromosome of)
IT Phospholipoproteins
RL: BIOL (Biological study)
(MBP (myelin basic protein), gene for, linkage mapping of rat)
IT Histocompatibility antigens
RL: BIOL (Biological study)
(MHC (major histocompatibility complex), gene for, linkage mapping of rat)
IT Glycoproteins, specific or class
RL: BIOL (Biological study)
(SVS II (seminal vesicle secretion II), gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(Svp-1 (seminal vesicle protein 1), gene for, linkage mapping of rat)
IT Kininogens
RL: BIOL (Biological study)
(T-, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(TCP-1, gene for, linkage mapping of rat)
IT Proteins, specific or class
RL: BIOL (Biological study)
(VAMP-2 (vesicle-assocd. membrane protein 2), gene for, mapping on rat chromosome of)

IT Receptors
RL: BIOL (Biological study)
(androgen, gene for, mapping on rat chromosome of)
IT Lipoproteins
RL: BIOL (Biological study)
(apo-, C-III, gene for, mapping on rat chromosome of)
IT Genetic element
RL: BIOL (Biological study)
(arbitrary **DNA** segment, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Sialoglycoproteins
RL: BIOL (Biological study)
(asialo-, receptors, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(asialoglycoprotein, gene for, mapping on rat chromosome of)
IT Ribonucleic acids, transfer
RL: BIOL (Biological study)
(aspartic acid-specific, gene for, mapping on rat chromosome of)
IT Glycolipoproteins
RL: BIOL (Biological study)
(band 3, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(calbindins, intestinal, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(cell surface-assocd., gene for, mapping on rat chromosome of)
IT Phosphoproteins
RL: BIOL (Biological study)
(connexins 43, gene for, mapping on rat chromosome of)
IT Phosphoproteins
RL: BIOL (Biological study)
(filaggrins, pro-, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(gene B, gene for, linkage mapping of rat)
IT Proteins, specific or class
RL: BIOL (Biological study)
(gene C, gene for, linkage mapping of rat)
IT Proteins, specific or class
RL: BIOL (Biological study)
(gene H, gene for, linkage mapping of rat)
IT Phosphoproteins
RL: BIOL (Biological study)
(gene c-myc, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(gene s-myc, gene for, mapping on rat chromosome of)
IT Corticosteroids
RL: BIOL (Biological study)
(gluco-, receptors, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(glucocorticosteroid, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(glucose-transporting, gene for, mapping on rat chromosome of)
IT Ribonucleic acids, transfer
RL: BIOL (Biological study)

(glutamic acid-specific, gene for, mapping on rat chromosome of)
IT Ribonucleic acids, transfer
RL: BIOL (Biological study)
(glycine-specific, gene for, mapping on rat chromosome of)
IT Lymphokines and Cytokines
RL: BIOL (Biological study)
(interleukin 6, gene for, mapping on rat chromosome of)
IT Ribonucleic acids, transfer
RL: BIOL (Biological study)
(leucine-specific, gene for, mapping on rat chromosome of)
IT Sialoglycoproteins
RL: BIOL (Biological study)
(leukosialins, gene for, mapping on rat chromosome of)
IT Agglutinins and **Lectins**
RL: BIOL (Biological study)
(mannose-binding protein A, gene for, mapping on rat chromosome of)
IT Deoxyribonucleic acids
RL: BIOL (Biological study)
(microsatellite, polymerase chain reaction-analyzed, for rat gene mapping)
IT Receptors
RL: BIOL (Biological study)
(muscarinic M3, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(nerve growth factor, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(peripherins (eye rod outer segment), gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(phosphorylation-uncoupling, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(potassium channel-forming, voltage-regulated, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(prolactin, gene for, mapping on rat chromosome of)
IT Glycoproteins, specific or class
RL: BIOL (Biological study)
(prostateins, C2, gene for, mapping on rat chromosome of)
IT Gene, animal
RL: BIOL (Biological study)
(pseudo-, mapping of rat, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 1, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 10, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 13, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 14, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 15, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 16, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 17, gene mapping on, PCR-analyzed microsatellite **DNA** in)

IT Chromosome
(rat 18, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 19, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 2, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 20, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 3, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 4, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 5, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 6, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 7, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 8, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat 9, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Chromosome
(rat X, gene mapping on, PCR-analyzed microsatellite **DNA** in)
IT Androgens
RL: BIOL (Biological study)
(receptors, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(serotoninergic S1A, gene for, mapping on rat chromosome of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(sodium channel-forming, II, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(tachykinin NK1, gene for, mapping on rat chromosome of)
IT Kinins (animal hormones)
RL: BIOL (Biological study)
(tachykinin NK1 receptors, gene for, mapping on rat chromosome of)
IT Lymphokines and Cytokines
RL: BIOL (Biological study)
(tumor necrosis factor, gene for, mapping on rat chromosome of)
IT Gene, animal
RL: BIOL (Biological study)
(B, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(FGG, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(FH, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(GDC-1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)

(GC, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(GH, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(GRL, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(KAL, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Lap-1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TGFA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TAT, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TCP1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TNF, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(TRY1, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Thy-1, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Ucp, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(MBP, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(MDH2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(IGF2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)

(IL-6, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Caseins, biological studies
Fetoproteins
Lactalbumins
Tropomyosins
RL: BIOL (Biological study)
(.alpha.-, gene for, mapping on rat chromosome of)
IT Animal growth regulators
RL: BIOL (Biological study)
(.alpha.-transforming growth factors, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(.alpha.1B-adrenergic, gene for, mapping on rat chromosome of)
IT Macroglobulins
RL: BIOL (Biological study)
(.alpha.2-, gene for, mapping on rat chromosome of)
IT Globulins, biological studies
RL: BIOL (Biological study)
(.alpha.2u-, gene for, mapping on rat chromosome of)
IT Receptors
RL: BIOL (Biological study)
(.beta.2-adrenergic, gene for, mapping on rat chromosome of)
IT Crystallins
RL: BIOL (Biological study)
(.gamma.-, gene for, mapping on rat chromosome of)
IT Gene, animal
RL: BIOL (Biological study)
(ALB, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(A2M, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ACO1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(APOC3, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Abp, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Ace, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Acph, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Afp, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal

RL: BIOL (Biological study)
(Ahd-2, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Amy-1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Ar, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Asgr, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(C, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CTRB, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CPA, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(CRYG, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Cat, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ENO2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Es-2, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Es-3, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(H, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(HBB, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Hp, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal

RL: BIOL (Biological study)
(Htr-1a, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(NPY, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PKC, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PND, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PPY, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(PRPS2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Pep-3, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Pgd, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Pthlh, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(RT1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(REN, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(SYB2, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(Smst, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(c-myc, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(ckb, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal

RL: BIOL (Biological study)
(lca, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(prl, mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT Gene, animal
RL: BIOL (Biological study)
(svp-1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite **DNA** in)
IT 9000-92-4, Amylase 9001-10-9, Pepsinogen A 9028-71-1 9075-65-4, .alpha.-Glycerophosphate dehydrogenase
RL: PRP (Properties)
(1, gene for, linkage mapping of rat)
IT 9004-06-2, Elastase
RL: PRP (Properties)
(1, gene for, mapping on rat chromosome of)
IT 9013-79-0, Esterase
RL: PRP (Properties)
(2 and 3 and 6, gene for, linkage mapping of rat)
IT 9028-86-8, Aldehyde dehydrogenase
RL: PRP (Properties)
(2, gene for, linkage mapping of rat)
IT 9014-08-8 11075-17-5, Carboxypeptidase A
RL: PRP (Properties)
(2, gene for, mapping on rat chromosome of)
IT 9031-96-3, Peptidase
RL: PRP (Properties)
(3, gene for, linkage mapping of rat)
IT 9029-97-4
RL: PRP (Properties)
(A, gene for, mapping on rat chromosome of)
IT 9004-07-3, Chymotrypsin B
RL: PRP (Properties)
(B, gene for, mapping on rat chromosome of)
IT 9024-25-3, Aconitase
RL: PRP (Properties)
(I, gene for, linkage mapping of rat)
IT 9002-07-7, Trypsin
RL: PRP (Properties)
(I, gene for, mapping on rat chromosome of)
IT 9001-59-6
RL: PRP (Properties)
(L type, gene for, mapping on rat chromosome of)
IT 9035-51-2, Cytochrome P 450, biological studies
RL: BIOL (Biological study)
(b/e, gene for, mapping on rat chromosome of)
IT 9015-83-2, Phosphoribosylpyrophosphate synthetase
RL: PRP (Properties)
(gene for subunit II of, mapping on rat chromosome of)
IT 57285-09-3, Inhibin
RL: PRP (Properties)
(gene for .alpha.-subunit of, mapping on rat chromosome of)
IT 9004-10-8, Insulin, biological studies
RL: BIOL (Biological study)
(gene for, linkage mapping of rat)
IT 9001-61-0, Leucine aminopeptidase 9001-82-5, Phosphogluconate dehydrogenase 9030-88-0, Serine:pyruvate aminotransferase 9032-88-6, Fumarate hydratase

RL: PRP (Properties)
(gene for, linkage mapping of rat)
IT 9002-62-4, Prolactin, biological studies 9002-72-6, Growth hormone
9015-94-5, Renin, biological studies
RL: BIOL (Biological study)
(gene for, mapping on rat chromosome of)
IT 1393-25-5, Secretin 9001-01-8, Kallikrein 9001-05-2, Catalase
9001-15-4 9001-36-9, Glucokinase 9013-08-5, Phosphoenolpyruvate carboxykinase 9014-55-5, Tyrosine aminotransferase 9015-82-1, Angiotensin I converting enzyme 9025-24-5, Carboxypeptidase B 9028-47-1D, malate dehydrogenase 9044-53-5, Steroid hydroxylase 9059-22-7, Heme oxygenase 11002-13-4, Angiotensinogen (protein renin substrate) 37274-61-6, Isovaleryl-CoA dehydrogenase 51110-01-1, Somatostatin 53414-68-9, Tonin 59763-91-6, Pancreatic **polypeptide** 67763-96-6, Insulin-like growth factor I 67763-97-7, Insulin-like growth factor II 73562-30-8, Acyl-peptide hydrolase 78689-77-7 79747-53-8, Protein tyrosine phosphatase 81611-75-8 82785-45-3, Neuropeptide Y 85637-73-6, Atrial natriuretic factor 103370-86-1, Humoral hypercalcemic factor 105844-41-5 117628-82-7, Follistatin
RL: PRP (Properties)
(gene for, mapping on rat chromosome of)
IT 102577-23-1, Neuromedin K
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(receptor, gene for, linkage mapping of rat)
IT 9061-61-4, Nerve growth factor 33507-63-0, Substance P
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(receptor, gene for, mapping on rat chromosome of)
IT 141436-78-4, Protein kinase C
RL: PRP (Properties)
(type I, gene for, mapping on rat chromosome of)

L12 ANSWER 11 OF 11 MEDLINE on STN
AN 93052391 MEDLINE
DN 93052391 PubMed ID: 1358809
TI Genetic map of nine polymorphic loci comprising a single linkage group on rat chromosome 10: evidence for linkage conservation with human chromosome 17 and mouse **chromosome 11**.
AU Remmers E F; Goldmuntz E A; Cash J M; Crofford L J; Misiewicz-Poltorak B; Zha H; Wilder R L
CS Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892.
SO GENOMICS, (1992 Nov) 14 (3) 618-23.
Journal code: 8800135. ISSN: 0888-7543.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199212
ED Entered STN: 19930122
Last Updated on STN: 19950206
Entered Medline: 19921217
AB Seven genes and two anonymous markers were mapped to a single linkage group on rat chromosome 10 using progeny of an F2 intercross of Fischer (F344/N) and Lewis (LEW/N) inbred rats. Two genes, the neu oncogene or cellular homologue of the viral oncogene erbb2 (ERBB2) and growth hormone (GH) were mapped by Southern blot analysis of restriction fragment length polymorphisms. Five genes, embryonic skeletal myosin heavy chain (MYH3), androgen binding protein/sex hormone binding globulin (SHBG),

asialoglycoprotein receptor (hepatic **lectin**)-1 (ASGR1), ATP citrate lysase (CLATP), and pancreatic **polypeptide** (PPY), and two anonymous markers, F16F2 and F10F1, were mapped using PCR amplification techniques. The PCR-typable polymorphic markers for the five genes were also highly polymorphic in 10 other inbred rat strains (SHR/N, WKY/N, MNR/N, MR/N, LOU/MN, BN/SsN, BUF/N, WBB1/N, WBB2/N, and ACI/N). These markers should be useful in genetic analysis of traits described in inbred rat strains, as well as in genetic monitoring of such strains. The loci in this linkage group covered 50 cM of rat chromosome 10 with the following order: MYH3, SHBG/ASGR1 (no recombinants detected), F16F2, ERBB2, CLATP, PPY, GH, and F10F1. Comparative gene mapping analysis indicated that this region of rat chromosome 10 exhibits linkage conservation with regions of human chromosome 17 and mouse **chromosome 11**.

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 07:46:32 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 SEP 2003  HIGHEST RN 593958-55-5
DICTIONARY FILE UPDATES:  26 SEP 2003  HIGHEST RN 593958-55-5

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d que l13
L13           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  SS3939/BI


=> d sqide3 l13 1-4

L13  ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   280786-71-2  REGISTRY
CN   249-374-Protein ss3939 (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   6: PN: WO0039296 SEQID: 6 claimed protein
FS   PROTEIN SEQUENCE
SQL  126

PATENT ANNOTATIONS (PNTE):
Sequence |Patent
Source   |Reference
=========+============
Not Given|WO2000039296
         |claimed
         |SEQID 6


SEQ3     1 Trp-Ile-Cys-Arg-Lys-Arg-Lys-Arg-Glu-Gln-
        11 Pro-Asp-Pro-Ser-Thr-Lys-Lys-Gln-His-Thr-
        21 Ile-Trp-Pro-Ser-Pro-His-Gln-Gly-Asn-Ser-
        31 Pro-Asp-Leu-Glu-Val-Tyr-Asn-Val-Ile-Arg-
        41 Lys-Gln-Ser-Glu-Ala-Asp-Leu-Ala-Glu-Thr-
        51 Arg-Pro-Asp-Leu-Lys-Asn-Ile-Ser-Phe-Arg-
        61 Val-Cys-Ser-Gly-Glu-Ala-Thr-Pro-Asp-Asp-
        71 Met-Ser-Cys-Asp-Tyr-Asp-Asn-Met-Ala-Val-
        81 Asn-Pro-Ser-Glu-Ser-Gly-Phe-Val-Thr-Leu-
        91 Val-Ser-Val-Glu-Ser-Gly-Phe-Val-Thr-Asn-
       101 Asp-Ile-Tyr-Glu-Phe-Ser-Pro-Asp-Gln-Met-
       111 Gly-Arg-Ser-Lys-Glu-Ser-Gly-Trp-Val-Glu-
```

121 Asn-Glu-Ile-Tyr-Gly-Tyr

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN
RN 280786-69-8 REGISTRY
CN **22-227-Protein ss3939 (human) (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: WO0039296 SEQID: 5 claimed protein
FS PROTEIN SEQUENCE
SQL 206

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2000039296 claimed SEQID 5

SEQ3
1 Ala-Thr-Gly-Arg-Leu-Leu-Ser-Gly-Gln-Pro-
11 Val-Cys-Arg-Gly-Gly-Thr-Gln-Arg-Pro-Cys-
21 Tyr-Lys-Val-Ile-Tyr-Phe-His-Asp-Thr-Ser-
31 Arg-Arg-Leu-Asn-Phe-Glu-Glu-Ala-Lys-Glu-
41 Ala-Cys-Arg-Arg-Asp-Gly-Gly-Gln-Leu-Val-
51 Ser-Ile-Glu-Ser-Glu-Asp-Glu-Gln-Lys-Leu-
61 Ile-Glu-Lys-Phe-Ile-Glu-Asn-Leu-Leu-Pro-
71 Ser-Asp-Gly-Asp-Phe-Trp-Ile-Gly-Leu-Arg-
81 Arg-Arg-Glu-Glu-Lys-Gln-Ser-Asn-Ser-Thr-
91 Ala-Cys-Gln-Asp-Leu-Tyr-Ala-Trp-Thr-Asp-
101 Gly-Ser-Ile-Ser-Gln-Phe-Arg-Asn-Trp-Tyr-
111 Val-Asp-Glu-Pro-Ser-Cys-Gly-Ser-Glu-Val-
121 Cys-Val-Val-Met-Tyr-His-Gln-Pro-Ser-Ala-
131 Pro-Ala-Gly-Ile-Gly-Gly-Pro-Tyr-Met-Phe-
141 Gln-Trp-Asn-Asp-Asp-Arg-Cys-Asn-Met-Lys-
151 Asn-Asn-Phe-Ile-Cys-Lys-Tyr-Ser-Asp-Glu-
161 Lys-Pro-Ala-Val-Pro-Ser-Arg-Glu-Ala-Glu-
171 Gly-Glu-Glu-Thr-Glu-Leu-Thr-Thr-Pro-Val-
181 Leu-Pro-Glu-Glu-Thr-Gln-Glu-Glu-Asp-Ala-
191 Lys-Lys-Thr-Phe-Lys-Glu-Ser-Arg-Glu-Ala-
201 Ala-Leu-Asn-Leu-Ala-Tyr

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN
RN 280786-68-7 REGISTRY
CN **Protein ss3939 (human) (9CI)** (CA INDEX NAME)
OTHER NAMES:

CN 1175: PN: WO0190304 SEQID: 2579 claimed protein
CN 15: PN: WO0142285 SEQID: 15 claimed protein
CN 2: PN: WO0039296 SEQID: 2 claimed protein
CN Protein (human clone HSLKC45).
CN Protein XMAD-15 (extracellular matrix and cell adhesion molecule) (human Incyte clone 3143411CD1 precursor)
FS PROTEIN SEQUENCE
SQL 374

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2000039296 claimed SEQID 2
	WO2001042285 claimed SEQID 15
	WO2001090304 claimed SEQID 2579

SEQ3
```
  1 Met-Arg-Pro-Gly-Thr-Ala-Leu-Gln-Ala-Val-
 11 Leu-Leu-Ala-Val-Leu-Leu-Val-Gly-Leu-Arg-
 21 Ala-Ala-Thr-Gly-Arg-Leu-Leu-Ser-Gly-Gln-
 31 Pro-Val-Cys-Arg-Gly-Gly-Thr-Gln-Arg-Pro-
 41 Cys-Tyr-Lys-Val-Ile-Tyr-Phe-His-Asp-Thr-
 51 Ser-Arg-Arg-Leu-Asn-Phe-Glu-Glu-Ala-Lys-
 61 Glu-Ala-Cys-Arg-Arg-Asp-Gly-Gly-Gln-Leu-
 71 Val-Ser-Ile-Glu-Ser-Glu-Asp-Glu-Gln-Lys-
 81 Leu-Ile-Glu-Lys-Phe-Ile-Glu-Asn-Leu-Leu-
 91 Pro-Ser-Asp-Gly-Asp-Phe-Trp-Ile-Gly-Leu-
101 Arg-Arg-Arg-Glu-Glu-Lys-Gln-Ser-Asn-Ser-
111 Thr-Ala-Cys-Gln-Asp-Leu-Tyr-Ala-Trp-Thr-
121 Asp-Gly-Ser-Ile-Ser-Gln-Phe-Arg-Asn-Trp-
131 Tyr-Val-Asp-Glu-Pro-Ser-Cys-Gly-Ser-Glu-
141 Val-Cys-Val-Val-Met-Tyr-His-Gln-Pro-Ser-
151 Ala-Pro-Ala-Gly-Ile-Gly-Gly-Pro-Tyr-Met-
161 Phe-Gln-Trp-Asn-Asp-Asp-Arg-Cys-Asn-Met-
171 Lys-Asn-Asn-Phe-Ile-Cys-Lys-Tyr-Ser-Asp-
181 Glu-Lys-Pro-Ala-Val-Pro-Ser-Arg-Glu-Ala-
191 Glu-Gly-Glu-Glu-Thr-Glu-Leu-Thr-Thr-Pro-
201 Val-Leu-Pro-Glu-Glu-Thr-Gln-Glu-Glu-Asp-
211 Ala-Lys-Lys-Thr-Phe-Lys-Glu-Ser-Arg-Glu-
221 Ala-Ala-Leu-Asn-Leu-Ala-Tyr-Ile-Leu-Ile-
231 Pro-Ser-Ile-Pro-Leu-Leu-Leu-Leu-Leu-Val-
241 Val-Thr-Thr-Val-Val-Cys-Trp-Val-Trp-Ile-
251 Cys-Arg-Lys-Arg-Lys-Arg-Glu-Gln-Pro-Asp-
261 Pro-Ser-Thr-Lys-Lys-Gln-His-Thr-Ile-Trp-
271 Pro-Ser-Pro-His-Gln-Gly-Asn-Ser-Pro-Asp-
281 Leu-Glu-Val-Tyr-Asn-Val-Ile-Arg-Lys-Gln-
291 Ser-Glu-Ala-Asp-Leu-Ala-Glu-Thr-Arg-Pro-
301 Asp-Leu-Lys-Asn-Ile-Ser-Phe-Arg-Val-Cys-
311 Ser-Gly-Glu-Ala-Thr-Pro-Asp-Asp-Met-Ser-
321 Cys-Asp-Tyr-Asp-Asn-Met-Ala-Val-Asn-Pro-
331 Ser-Glu-Ser-Gly-Phe-Val-Thr-Leu-Val-Ser-
```

```
       341 Val-Glu-Ser-Gly-Phe-Val-Thr-Asn-Asp-Ile-
       351 Tyr-Glu-Phe-Ser-Pro-Asp-Gln-Met-Gly-Arg-
       361 Ser-Lys-Glu-Ser-Gly-Trp-Val-Glu-Asn-Glu-
       371 Ile-Tyr-Gly-Tyr


**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
                3 REFERENCES IN FILE CA (1907 TO DATE)
                1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
                3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13  ANSWER 4 OF 4  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   280786-67-6  REGISTRY
CN   DNA (human protein ss3939 cDNA plus flanks) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   1: PN: WO0039296 SEQID: 1 claimed DNA
FS   NUCLEIC ACID SEQUENCE
SQL  2005
NA   564 a   469 c   514 g   458 t
NTE  doublestranded

PATENT ANNOTATIONS (PNTE):
Sequence    |Patent
Source      |Reference
============+============
Homo sapiens|WO2000039296
            |claimed
            |SEQID 1


SEQ      1 tgtcgcgcac gcctctgccc gccagcccgc tccaccgccg tagcgcccga
        51 gtgtcggggg gcgcacccga gtcgggccat gaggccggga accgcgctac
       101 aggccgtgct gctggccgtg ctgctggtgg ggctgcgggc cgcgacgggt
       151 cgcctgctga gtgggcagcc agtctgccgg ggagggacac agaggccttg
       201 ttataaagtc atttacttcc atgatacttc tcgaagactg aactttgagg
       251 aagccaaaga agcctgcagg agggatggag gccagctagt cagcatcgag
       301 tctgaagatg aacagaaact gatagaaaag ttcattgaaa acctcttgcc
       351 atctgatggt gacttctgga ttgggctcag gaggcgtgag gagaaacaaa
       401 gcaatagcac agcctgccag gacctttatg cttggactga tggcagcata
       451 tcacaattta ggaactggta tgtggatgag ccgtcctgcg gcagcgaggt
       501 ctgcgtggtc atgtaccatc agccatcggc acccgctggc atcggaggcc
       551 cctacatgtt ccagtggaat gatgaccggt gcaacatgaa gaacaatttc
       601 atttgcaaat attctgatga gaaaccagca gttccttcta gagaagctga
       651 aggtgaggaa acagagctga caacacctgt acttccagaa gaaacacagg
       701 aagaagatgc caaaaaaaca tttaaagaaa gtagagaagc tgccttgaat
       751 ctggcctaca tcctaatccc cagcattccc cttctcctcc tccttgtggt
       801 caccacagtt gtatgttggg tttggatctg tagaaaaaga aaacgggagc
       851 agccagaccc tagcacaaag aagcaacaca ccatctggcc ctctcctcac
       901 cagggaaaca gcccggacct agaggtctac aatgtcataa gaaaacaaag
       951 cgaagctgac ttagctgaga cccggccaga cctgaagaat atttcattcc
      1001 gagtgtgttc gggagaagcc actcccgatg acatgtcttg tgactatgac
      1051 aacatggctg tgaacccatc agaaagtggg tttgtgactc tggtgagcgt
      1101 ggagagtgga tttgtgacca atgacattta tgagttctcc ccagaccaaa
      1151 tggggaggag taaggagtct ggatgggtgg aaaatgaaat atatggttat
      1201 taggacatat aaaaaactga aactgacaac aatggaaaag aaatgataag
```

```
      1251 caaaatcctc ttattttcta taaggaaaat acacagaagg tctatgaaca
      1301 agcttagatc aggtcctgtg gatgagcatg tggtccccac gacctcctgt
      1351 tggaccccca cgttttggct gtatccttta tcccagccag tcatccagct
      1401 cgaccttatg agaaggtacc ttgcccaggt ctggcacata gtagagtctc
      1451 aataaatgtc acttggttgg ttgtatctaa cttttaaggg acagagcttt
      1501 acctggcagt gataaagatg ggctgtggag cttggaaaac cacctctgtt
      1551 ttccttgctc tatacagcag cacatattat catacagaca gaaaatccag
      1601 aatcttttca aagcccacat atggtagcac aggttggcct gtgcatcggc
      1651 aattctcata tctgtttttt tcaaagaata aaatcaaata aagagcagga
      1701 aacagagtgt tagtctgtgt ctacagccct tcctctgcat gtggccacag
      1751 gggacctttt tttgtttctc ctgacatcca gacttggaaa tatctaacta
      1801 cttgcaaaac taaaaatgag gccaggcgca gtggctgacg cctgtaatcc
      1851 cagaaccttg ggagaccaag attggaggat agcttgagtt caggagttcc
      1901 agaccttcct gggcaaaata gtgagactct gactctacaa aaaatttaaa
      1951 aattagcagg gcatggtggc atgcgcctgc agtcccagct actcaggagg
      2001 ccgag

MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
                  1 REFERENCES IN FILE CA (1907 TO DATE)
                  1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 07:47:00 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Sep 2003  VOL 139 ISS 14
FILE LAST UPDATED: 28 Sep 2003  (20030928/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que l14
L13           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  SS3939/BI
L14           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13


=> d bib l14 1-3

L14  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2003 ACS on STN
AN   2001:868629  HCAPLUS
DN   136:15957
```

TI Human nucleic acids and their encoded proteins and antibodies
IN Birse, Charles E.; Rosen, Craig A.
PA Human Genome Sciences, Inc.; USA
SO PCT Int. Appl., 2081 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 91

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090304	A2	20011129	WO 2001-US16450	20010518
	WO 2001090304	A3	20020510		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001041411	A5	20010820	AU 2001-41411	20010208
	AU 2001074888	A5	20011203	AU 2001-74888	20010518
PRAI	US 2000-205515P	P	20000519		
	US 2000-241221P	P	20001020		
	US 2000-241786P	P	20001020		
	WO 2001-US16450	W	20010518		

L14 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:435111 HCAPLUS
DN 135:29911
TI DNA encoding twenty-one human extracellular matrix and cell adhesion molecules
IN Yue, Henry; Tang, Y. Tom; Lal, Preeti; Burford, Neil; Azimzai, Yalda; Patterson, Chandra; Baughn, Mariah R.; Lu, Dyung Aina M.; Shah, Purvi; Au-young, Janice
PA Incyte Genomics, Inc., USA; et al.
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042285	A2	20010614	WO 2000-US32990	20001205
	WO 2001042285	A3	20020307		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1244695	A2	20021002	EP 2000-989218	20001205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003044913	A1	20030306	US 2002-149819	20020610
PRAI	US 1999-172852P	P	19991210		

US 1999-172354P P 19991216
WO 2000-US32990 W 20001205

L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:457208 HCAPLUS
DN 133:85160
TI Protein and cDNA sequences of human protein ss3939, which has homology to C-type lectins
IN Anderson, Dirk A.
PA Immunex Corporation, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000039296	A1	20000706	WO 1999-US30523	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002058310	A1	20020516	US 2001-887855	20010622
PRAI US 1998-113820P	P	19981223		
WO 1999-US30523	A1	19991222		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT